InstitutionMD Anderson
Address1400 Pressler St
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Lee JJ, Yin G. Principles and Reporting of Bayesian Trials. J Thorac Oncol. 2021 01; 16(1):30-36. PMID: 33229069; PMCID: PMC10127518.
      Citations:    Fields:    Translation:Humans
    2. Tang C, Sherman SI, Price M, Weng J, Davis SE, Hong DS, Yao JC, Buzdar A, Wilding G, Lee JJ. Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement. Clin Cancer Res. 2017 Mar 15; 23(6):1414-1421. PMID: 28275168; PMCID: PMC5354950.
      Citations: 13     Fields:    Translation:Humans
    3. Jardim DL, Fontes Jardim DL, Schwaederle M, Wei C, Lee JJ, Hong DS, Eggermont AM, Schilsky RL, Mendelsohn J, Lazar V, Kurzrock R. Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval. J Natl Cancer Inst. 2015 Nov; 107(11). PMID: 26378224; PMCID: PMC4857149.
      Citations: 75     Fields:    Translation:Humans
    4. Schwaederle M, Zhao M, Lee JJ, Eggermont AM, Schilsky RL, Mendelsohn J, Lazar V, Kurzrock R. Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. J Clin Oncol. 2015 Nov 10; 33(32):3817-25. PMID: 26304871; PMCID: PMC4737863.
      Citations: 160     Fields:    Translation:Humans
    5. Komaki R, Allen PK, Wei X, Blumenschein GR, Tang X, Lee JJ, Welsh JW, Wistuba II, Liu DD, Hong WK. Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):317-24. PMID: 25968826; PMCID: PMC4432249.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    6. Massarelli E, Lin H, Ginsberg LE, Tran HT, Lee JJ, Canales JR, Williams MD, Blumenschein GR, Lu C, Heymach JV, Kies MS, Papadimitrakopoulou V. Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2015 Jul; 26(7):1476-80. PMID: 26025965; PMCID: PMC4855241.
      Citations: 34     Fields:    Translation:HumansCTClinical Trials
    7. Gold KA, Lin HY, Swisher SG, Xing Y, Lee JJ, Kim ES, William WN, Zhang J. Relationship between tumor size and survival in non-small-cell lung cancer (NSCLC): an analysis of the surveillance, epidemiology, and end results (SEER) registry. J Thorac Oncol. 2015 Apr; 10(4):682-90. PMID: 25590605; PMCID: PMC4368494.
      Citations: 56     Fields:    Translation:Humans
    8. Lee JJ. Commentary on Hey and Kimmelman. Clin Trials. 2015 Apr; 12(2):110-2. PMID: 25649110; PMCID: PMC4492278.
      Citations: 8     Fields:    Translation:Humans
    9. Staquicini FI, Qian MD, Salameh A, Dobroff AS, Edwards JK, Cimino DF, Moeller BJ, Kelly P, Nunez MI, Tang X, Liu DD, Lee JJ, Hong WK, Ferrara F, Bradbury AR, Lobb RR, Edelman MJ, Sidman RL, Wistuba II, Arap W, Pasqualini R. Receptor tyrosine kinase EphA5 is a functional molecular target in human lung cancer. J Biol Chem. 2015 Mar 20; 290(12):7345-59. PMID: 25623065; PMCID: PMC4367244.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    10. Tong P, Coombes KR, Johnson FM, Byers LA, Diao L, Liu DD, Lee JJ, Heymach JV, Wang J. drexplorer: A tool to explore dose-response relationships and drug-drug interactions. Bioinformatics. 2015 May 15; 31(10):1692-4. PMID: 25600946; PMCID: PMC4426846.
      Citations: 16     Fields:    
    11. Wheler J, Lee JJ, Kurzrock R. Unique molecular landscapes in cancer: implications for individualized, curated drug combinations. Cancer Res. 2014 Dec 15; 74(24):7181-4. PMID: 25326492; PMCID: PMC4292868.
      Citations: 32     Fields:    Translation:Humans
    12. Zhang J, Fujimoto J, Zhang J, Wedge DC, Song X, Zhang J, Seth S, Chow CW, Cao Y, Gumbs C, Gold KA, Kalhor N, Little L, Mahadeshwar H, Moran C, Protopopov A, Sun H, Tang J, Wu X, Ye Y, William WN, Lee JJ, Heymach JV, Hong WK, Swisher S, Wistuba II, Futreal PA. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science. 2014 Oct 10; 346(6206):256-9. PMID: 25301631; PMCID: PMC4354858.
      Citations: 432     Fields:    Translation:Humans
    13. Pickering CR, Zhou JH, Lee JJ, Drummond JA, Peng SA, Saade RE, Tsai KY, Curry JL, Tetzlaff MT, Lai SY, Yu J, Muzny DM, Doddapaneni H, Shinbrot E, Covington KR, Zhang J, Seth S, Caulin C, Clayman GL, El-Naggar AK, Gibbs RA, Weber RS, Myers JN, Wheeler DA, Frederick MJ. Mutational landscape of aggressive cutaneous squamous cell carcinoma. Clin Cancer Res. 2014 Dec 15; 20(24):6582-92. PMID: 25303977; PMCID: PMC4367811.
      Citations: 210     Fields:    Translation:Humans
    14. Ganesan P, Moulder S, Lee JJ, Janku F, Valero V, Zinner RG, Naing A, Fu S, Tsimberidou AM, Hong D, Stephen B, Stephens P, Yelensky R, Meric-Bernstam F, Kurzrock R, Wheler JJ. Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents. Mol Cancer Ther. 2014 Dec; 13(12):3175-84. PMID: 25253784; PMCID: PMC4258414.
      Citations: 16     Fields:    Translation:HumansCells
    15. Riquelme E, Suraokar M, Behrens C, Lin HY, Girard L, Nilsson MB, Simon G, Wang J, Coombes KR, Lee JJ, Hong WK, Heymach J, Minna JD, Wistuba II. VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapy. Clin Cancer Res. 2014 Jul 15; 20(14):3849-61. PMID: 24850841; PMCID: PMC4190586.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    16. Wheler JJ, Parker BA, Lee JJ, Atkins JT, Janku F, Tsimberidou AM, Zinner R, Subbiah V, Fu S, Schwab R, Moulder S, Valero V, Schwaederle M, Yelensky R, Miller VA, Stephens MP, Meric-Bernstam F, Kurzrock R. Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms. Oncotarget. 2014 May 15; 5(9):2349-54. PMID: 24811890; PMCID: PMC4058010.
      Citations: 34     Fields:    Translation:Humans
    17. Nunez MI, Behrens C, Liu D, Lin YH, Lee JJ, Roth J, Heymach J, Swisher SG, Hong WK, Wistuba II, Stewart DJ. Membrane carbonic anhydrase IX expression and relapse risk in resected stage I-II non-small-cell lung cancer. J Thorac Oncol. 2014 May; 9(5):675-84. PMID: 24662455; PMCID: PMC4084898.
      Citations: 8     Fields:    Translation:Humans
    18. Carey TE, William WN, Nguyen ML, Ko EC, Riddell J, Pai SI, Gupta V, Walline HM, Lee JJ, Wolf GT, Shin DM, Grandis JR, Ferris RL, D'souza G. Epidemiology of head and neck squamous cell cancer among HIV-infected patients. J Acquir Immune Defic Syndr. 2014 Apr 15; 65(5):603-10. PMID: 24326607; PMCID: PMC3999230.
      Citations: 30     Fields:    Translation:Humans
    19. Benjamin RS, Lee JJ. One step forward, two steps back. Lancet Oncol. 2014 Apr; 15(4):366-7. PMID: 24694628.
      Citations: 4     Fields:    Translation:Humans
    20. Suraokar MB, Nunez MI, Diao L, Chow CW, Kim D, Behrens C, Lin H, Lee S, Raso G, Moran C, Rice D, Mehran R, Lee JJ, Pass HI, Wang J, Momin AA, James BP, Corvalan A, Coombes K, Tsao A, Wistuba II. Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications. Ann Oncol. 2014 Jun; 25(6):1184-92. PMID: 24669013; PMCID: PMC4037861.
      Citations: 26     Fields:    Translation:HumansCells
    21. Tsao AS, Harun N, Fujimoto J, Devito V, Lee JJ, Kuhn E, Mehran R, Rice D, Moran C, Hong WK, Shen L, Suraokar M, Wistuba I. Elevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesothelioma. Ann Diagn Pathol. 2014 Jun; 18(3):140-5. PMID: 24747001; PMCID: PMC4136493.
      Citations: 4     Fields:    Translation:Humans
    22. Janku F, Hong DS, Fu S, Piha-Paul SA, Naing A, Falchook GS, Tsimberidou AM, Stepanek VM, Moulder SL, Lee JJ, Zinner RG, Broaddus RR, Wheler JJ, Kurzrock R, Luthra R. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep. 2014 Jan 30; 6(2):377-87. PMID: 24440717; PMCID: PMC4409143.
      Citations: 120     Fields:    Translation:HumansCTClinical Trials
    23. Kim JS, Kim ES, Liu D, Lee JJ, Solis L, Behrens C, Lippman SM, Hong WK, Wistuba II, Lee HY. Prognostic implications of tumoral expression of insulin like growth factors 1 and 2 in patients with non-small-cell lung cancer. Clin Lung Cancer. 2014 May; 15(3):213-21. PMID: 24485233; PMCID: PMC4572464.
      Citations: 12     Fields:    Translation:Humans
    24. Tsao AS, Harun N, Lee JJ, Heymach J, Pisters K, Hong WK, Fujimoto J, Wistuba I. Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma. Clin Lung Cancer. 2014 May; 15(3):197-201. PMID: 24492162; PMCID: PMC5080907.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    25. Gold KA, Kim ES, Liu DD, Yuan P, Behrens C, Solis LM, Kadara H, Rice DC, Wistuba II, Swisher SG, Hofstetter WL, Lee JJ, Hong WK. Prediction of survival in resected non-small cell lung cancer using a protein expression-based risk model: implications for personalized chemoprevention and therapy. Clin Cancer Res. 2014 Apr 01; 20(7):1946-54. PMID: 24366692; PMCID: PMC4018222.
      Citations: 19     Fields:    Translation:HumansCells
    26. Saintigny P, Liu S, Kim ES, Tsao AS, Herbst RS, Alden C, Lee JJ, Tang X, Stewart DJ, Kies MS, Fossella FV, Tran HT, Mao L, Hicks ME, Erasmus J, Gupta S, Girard L, Peyton M, Diao L, Wang J, Davis SE, Minna JD, Wistuba I, Hong WK, Heymach JV, Lippman SM, Blumenschein GR. Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial. Clin Cancer Res. 2013 Dec 15; 19(24):6967-75. PMID: 24166906; PMCID: PMC3905243.
      Citations: 28     Fields:    Translation:Humans
    27. Behrens C, Solis LM, Lin H, Yuan P, Tang X, Kadara H, Riquelme E, Galindo H, Moran CA, Kalhor N, Swisher SG, Simon GR, Stewart DJ, Lee JJ, Wistuba II. EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma. Clin Cancer Res. 2013 Dec 01; 19(23):6556-65. PMID: 24097870; PMCID: PMC3890101.
      Citations: 77     Fields:    Translation:Humans
    28. Ganesan P, Janku F, Naing A, Hong DS, Tsimberidou AM, Falchook GS, Wheler JJ, Piha-Paul SA, Fu S, Stepanek VM, Lee JJ, Luthra R, Overman MJ, Kopetz ES, Wolff RA, Kurzrock R. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. Mol Cancer Ther. 2013 Dec; 12(12):2857-63. PMID: 24092809; PMCID: PMC4158732.
      Citations: 18     Fields:    Translation:HumansCells
    29. Gu X, Yin G, Lee JJ. Bayesian two-step Lasso strategy for biomarker selection in personalized medicine development for time-to-event endpoints. Contemp Clin Trials. 2013 Nov; 36(2):642-50. PMID: 24075829; PMCID: PMC3873734.
      Citations: 6     Fields:    Translation:Humans
    30. Bau DT, Lippman SM, Xu E, Gong Y, Lee JJ, Wu X, Gu J. Short telomere lengths in peripheral blood leukocytes are associated with an increased risk of oral premalignant lesion and oral squamous cell carcinoma. Cancer. 2013 Dec 15; 119(24):4277-83. PMID: 24105340; PMCID: PMC3855186.
      Citations: 16     Fields:    Translation:HumansCells
    31. Yao JC, Meric-Bernstam F, Lee JJ, Eckhardt SG. Accelerated approval and breakthrough therapy designation: oncology drug development on speed? Clin Cancer Res. 2013 Aug 15; 19(16):4305-8. PMID: 23833307; PMCID: PMC4167364.
      Citations: 3     Fields:    Translation:Humans
    32. Chen JQ, Bao Y, Lee J, Murray JL, Litton JK, Xiao L, Zhou R, Wu Y, Shen XY, Zhang H, Sahin AA, Katz RL, Bondy ML, Berinstein NL, Hortobagyi GN, Radvanyi LG. Prognostic value of the trichorhinophalangeal syndrome-1 (TRPS-1), a GATA family transcription factor, in early-stage breast cancer. Ann Oncol. 2013 Oct; 24(10):2534-2542. PMID: 23729783; PMCID: PMC3784330.
      Citations: 8     Fields:    Translation:Humans
    33. Kabbout M, Garcia MM, Fujimoto J, Liu DD, Woods D, Chow CW, Mendoza G, Momin AA, James BP, Solis L, Behrens C, Lee JJ, Wistuba II, Kadara H. ETS2 mediated tumor suppressive function and MET oncogene inhibition in human non-small cell lung cancer. Clin Cancer Res. 2013 Jul 01; 19(13):3383-95. PMID: 23659968; PMCID: PMC3846434.
      Citations: 67     Fields:    Translation:HumansCells
    34. Said R, Hong DS, Warneke CL, Lee JJ, Wheler JJ, Janku F, Naing A, Falchook GS, Fu S, Piha-Paul S, Tsimberidou AM, Kurzrock R. P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy. Oncotarget. 2013 May; 4(5):705-14. PMID: 23670029; PMCID: PMC3742831.
      Citations: 64     Fields:    Translation:Humans
    35. Tsao AS, Liu S, Lee JJ, Alden CM, Blumenschein GR, Herbst R, Davis SE, Kim E, Lippman S, Heymach J, Tran H, Tang X, Wistuba I, Hong WK. Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial. J Thorac Oncol. 2013 May; 8(5):658-61. PMID: 23584298; PMCID: PMC5118909.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    36. Jain RK, Lee JJ, Hong D, Kurzrock R. RE: Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials. J Natl Cancer Inst. 2013 Jun 05; 105(11):833. PMID: 23628598.
      Citations:    Fields:    Translation:Humans
    37. Tam AL, Kim ES, Lee JJ, Ensor JE, Hicks ME, Tang X, Blumenschein GR, Alden CM, Erasmus JJ, Tsao A, Lippman SM, Hong WK, Wistuba II, Gupta S. Feasibility of image-guided transthoracic core-needle biopsy in the BATTLE lung trial. J Thorac Oncol. 2013 Apr; 8(4):436-42. PMID: 23442309; PMCID: PMC3879952.
      Citations: 31     Fields:    Translation:Humans
    38. Chen N, Lee JJ. Optimal continuous-monitoring design of single-arm phase II trial based on the simulated annealing method. Contemp Clin Trials. 2013 May; 35(1):170-8. PMID: 23545075; PMCID: PMC3741066.
      Citations: 1     Fields:    
    39. Zhong LP, Zhu DW, William WN, Liu Y, Ma J, Yang CZ, Yang X, Wang LZ, Li J, Myers JN, Lee JJ, Zhang CP, Zhang ZY. Elevated cyclin D1 expression is predictive for a benefit from TPF induction chemotherapy in oral squamous cell carcinoma patients with advanced nodal disease. Mol Cancer Ther. 2013 Jun; 12(6):1112-21. PMID: 23515614; PMCID: PMC5247265.
      Citations: 12     Fields:    Translation:HumansCells
    40. William WN, Pataer A, Kalhor N, Correa AM, Rice DC, Wistuba II, Heymach J, Lee JJ, Kim ES, Munden R, Gold KA, Papadimitrakopoulou V, Swisher SG, Erasmus JJ, University of Texas M.D. Anderson Lung Cancer Collaborative Research Group. Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy. J Thorac Oncol. 2013 Feb; 8(2):222-8. PMID: 23287849; PMCID: PMC3549050.
      Citations: 40     Fields:    Translation:Humans
    41. Jain RK, Lee JJ, Hong D, Kurzrock R. Reply to A. Levy et al. J Clin Oncol. 2013 Jan 20; 31(3):396. PMID: 23451354.
      Citations:    Fields:    Translation:Humans
    42. Jiang F, Jack Lee J, M?ller P. A Bayesian decision-theoretic sequential response-adaptive randomization design. Stat Med. 2013 May 30; 32(12):1975-94. PMID: 23315678; PMCID: PMC3873748.
      Citations: 5     Fields:    Translation:Humans
    43. Janku F, Wheler JJ, Naing A, Stepanek VM, Falchook GS, Fu S, Garrido-Laguna I, Tsimberidou AM, Piha-Paul SA, Moulder SL, Lee JJ, Luthra R, Hong DS, Kurzrock R. PIK3CA mutations in advanced cancers: characteristics and outcomes. Oncotarget. 2012 Dec; 3(12):1566-75. PMID: 23248156; PMCID: PMC3681495.
      Citations: 47     Fields:    Translation:Humans
    44. Fujimoto J, Kadara H, Garcia MM, Kabbout M, Behrens C, Liu DD, Lee JJ, Solis LM, Kim ES, Kalhor N, Moran C, Sharafkhaneh A, Lotan R, Wistuba II. G-protein coupled receptor family C, group 5, member A (GPRC5A) expression is decreased in the adjacent field and normal bronchial epithelia of patients with chronic obstructive pulmonary disease and non-small-cell lung cancer. J Thorac Oncol. 2012 Dec; 7(12):1747-1754. PMID: 23154545; PMCID: PMC3622592.
      Citations: 21     Fields:    Translation:Humans
    45. Saintigny P, Massarelli E, Lin S, Ahn YH, Chen Y, Goswami S, Erez B, O'Reilly MS, Liu D, Lee JJ, Zhang L, Ping Y, Behrens C, Solis Soto LM, Heymach JV, Kim ES, Herbst RS, Lippman SM, Wistuba II, Hong WK, Kurie JM, Koo JS. CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. Cancer Res. 2013 Jan 15; 73(2):571-82. PMID: 23204236; PMCID: PMC3548940.
      Citations: 88     Fields:    Translation:HumansAnimalsCells
    46. Zhong LP, Zhang CP, Ren GX, Guo W, William WN, Sun J, Zhu HG, Tu WY, Li J, Cai YL, Wang LZ, Fan XD, Wang ZH, Hu YJ, Ji T, Yang WJ, Ye WM, Li J, He Y, Wang YA, Xu LQ, Wang BS, Kies MS, Lee JJ, Myers JN, Zhang ZY. Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol. 2013 Feb 20; 31(6):744-51. PMID: 23129742; PMCID: PMC5569675.
      Citations: 90     Fields:    Translation:HumansCTClinical Trials
    47. Tsao AS, Liu S, Lee JJ, Alden C, Blumenschein G, Herbst R, Davis SE, Kim E, Lippman S, Stewart D, Tang XM, Wistuba I, Hong WK. Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial. J Thorac Oncol. 2012 Nov; 7(11):1645-52. PMID: 23059780; PMCID: PMC5161038.
      Citations: 8     Fields:    Translation:Humans
    48. Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN, Wistuba II, Coombes KR, Minna JD, Heymach JV. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res. 2013 Jan 01; 19(1):279-90. PMID: 23091115; PMCID: PMC3567921.
      Citations: 463     Fields:    Translation:HumansAnimalsCells
    49. Kadara H, Shen L, Fujimoto J, Saintigny P, Chow CW, Lang W, Chu Z, Garcia M, Kabbout M, Fan YH, Behrens C, Liu DA, Mao L, Lee JJ, Gold KA, Wang J, Coombes KR, Kim ES, Hong WK, Wistuba II. Characterizing the molecular spatial and temporal field of injury in early-stage smoker non-small cell lung cancer patients after definitive surgery by expression profiling. Cancer Prev Res (Phila). 2013 Jan; 6(1):8-17. PMID: 23087048; PMCID: PMC3774536.
      Citations: 22     Fields:    Translation:HumansCellsCTClinical Trials
    50. Janku F, Wheler JJ, Naing A, Falchook GS, Hong DS, Stepanek VM, Fu S, Piha-Paul SA, Lee JJ, Luthra R, Tsimberidou AM, Kurzrock R. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res. 2013 Jan 01; 73(1):276-84. PMID: 23066039; PMCID: PMC3537862.
      Citations: 141     Fields:    Translation:HumansCells
    51. Xue Y, Ren H, Xiao W, Chu Z, Lee JJ, Mao L. Antitumor activity of AZ64 via G2/M arrest in non-small cell lung cancer. Int J Oncol. 2012 Nov; 41(5):1798-808. PMID: 22948297.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    52. Zhang L, Poh CF, Williams M, Laronde DM, Berean K, Gardner PJ, Jiang H, Wu L, Lee JJ, Rosin MP. Loss of heterozygosity (LOH) profiles--validated risk predictors for progression to oral cancer. Cancer Prev Res (Phila). 2012 Sep; 5(9):1081-9. PMID: 22911111; PMCID: PMC3793638.
      Citations: 52     Fields:    Translation:Humans
    53. Kim ES, Lee JJ, He G, Chow CW, Fujimoto J, Kalhor N, Swisher SG, Wistuba II, Stewart DJ, Siddik ZH. Tissue platinum concentration and tumor response in non-small-cell lung cancer. J Clin Oncol. 2012 Sep 20; 30(27):3345-52. PMID: 22891266; PMCID: PMC3438232.
      Citations: 38     Fields:    Translation:Humans
    54. Bai H, Wang Z, Chen K, Zhao J, Lee JJ, Wang S, Zhou Q, Zhuo M, Mao L, An T, Duan J, Yang L, Wu M, Liang Z, Wang Y, Kang X, Wang J. Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. J Clin Oncol. 2012 Sep 01; 30(25):3077-83. PMID: 22826274; PMCID: PMC5321076.
      Citations: 101     Fields:    Translation:Humans
    55. Lee J, Bartholomeusz C, Krishnamurthy S, Liu P, Saso H, Lafortune TA, Hortobagyi GN, Ueno NT. PEA-15 unphosphorylated at both serine 104 and serine 116 inhibits ovarian cancer cell tumorigenicity and progression through blocking ?-catenin. Oncogenesis. 2012 Jul 16; 1:e22. PMID: 23552738; PMCID: PMC3412650.
      Citations: 19     
    56. Lee JJ, Chen N, Yin G. Worth adapting? Revisiting the usefulness of outcome-adaptive randomization. Clin Cancer Res. 2012 Sep 01; 18(17):4498-507. PMID: 22753588; PMCID: PMC3495976.
      Citations: 21     Fields:    Translation:Humans
    57. Lee JJ, Chu CT. Bayesian clinical trials in action. Stat Med. 2012 Nov 10; 31(25):2955-72. PMID: 22711340; PMCID: PMC3495977.
      Citations: 58     Fields:    
    58. Jain RK, Lee JJ, Ng C, Hong D, Gong J, Naing A, Wheler J, Kurzrock R. Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. J Clin Oncol. 2012 Jul 20; 30(21):2684-90. PMID: 22689801; PMCID: PMC3413279.
      Citations: 38     Fields:    Translation:Humans
    59. Hildebrandt MA, Lippman SM, Etzel CJ, Kim E, Lee JJ, Khuri FR, Spitz MR, Lotan R, Hong WK, Wu X. Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemoprevention. Clin Cancer Res. 2012 Jul 01; 18(13):3705-13. PMID: 22577058; PMCID: PMC3404728.
      Citations: 16     Fields:    Translation:HumansCells
    60. Pierce MC, Schwarz RA, Bhattar VS, Mondrik S, Williams MD, Lee JJ, Richards-Kortum R, Gillenwater AM. Accuracy of in vivo multimodal optical imaging for detection of oral neoplasia. Cancer Prev Res (Phila). 2012 Jun; 5(6):801-9. PMID: 22551901; PMCID: PMC3560936.
      Citations: 49     Fields:    Translation:Humans
    61. Pataer A, Kalhor N, Correa AM, Raso MG, Erasmus JJ, Kim ES, Behrens C, Lee JJ, Roth JA, Stewart DJ, Vaporciyan AA, Wistuba II, Swisher SG, University of Texas M. D. Anderson Lung Cancer Collaborative Research Group. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. J Thorac Oncol. 2012 May; 7(5):825-32. PMID: 22481232; PMCID: PMC3465940.
      Citations: 109     Fields:    Translation:Humans
    62. Nunez MI, Behrens C, Woods DM, Lin H, Suraokar M, Kadara H, Hofstetter W, Kalhor N, Lee JJ, Franklin W, Stewart DJ, Wistuba II. High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation. J Thorac Oncol. 2012 May; 7(5):833-40. PMID: 22729036; PMCID: PMC3383601.
      Citations: 52     Fields:    Translation:Humans
    63. Lu C, Stewart DJ, Lee JJ, Ji L, Ramesh R, Jayachandran G, Nunez MI, Wistuba II, Erasmus JJ, Hicks ME, Grimm EA, Reuben JM, Baladandayuthapani V, Templeton NS, McMannis JD, Roth JA. Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans. PLoS One. 2012; 7(4):e34833. PMID: 22558101; PMCID: PMC3338819.
      Citations: 58     Fields:    Translation:HumansCTClinical Trials
    64. Bekelman JE, Deye JA, Vikram B, Bentzen SM, Bruner D, Curran WJ, Dignam J, Efstathiou JA, FitzGerald TJ, Hurkmans C, Ibbott GS, Lee JJ, Merchant TE, Michalski J, Palta JR, Simon R, Ten Haken RK, Timmerman R, Tunis S, Coleman CN, Purdy J. Redesigning radiotherapy quality assurance: opportunities to develop an efficient, evidence-based system to support clinical trials--report of the National Cancer Institute Work Group on Radiotherapy Quality Assurance. Int J Radiat Oncol Biol Phys. 2012 Jul 01; 83(3):782-90. PMID: 22425219; PMCID: PMC3361528.
      Citations: 25     Fields:    Translation:Humans
    65. Kim WY, Prudkin L, Feng L, Kim ES, Hennessy B, Lee JS, Lee JJ, Glisson B, Lippman SM, Wistuba II, Hong WK, Lee HY. Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors. Cancer. 2012 Aug 15; 118(16):3993-4003. PMID: 22359227; PMCID: PMC3674414.
      Citations: 23     Fields:    Translation:HumansAnimalsCells
    66. Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, Lu KH, Kurzrock R. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol. 2012 Mar 10; 30(8):777-82. PMID: 22271473; PMCID: PMC3295566.
      Citations: 225     Fields:    Translation:Humans
    67. Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, Tsao A, Liu S, Larsen JE, Wang J, Diao L, Coombes KR, Chen L, Zhang S, Abdelmelek MF, Tang X, Papadimitrakopoulou V, Minna JD, Lippman SM, Hong WK, Herbst RS, Wistuba II, Heymach JV, Powis G. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst. 2012 Feb 08; 104(3):228-39. PMID: 22247021; PMCID: PMC3274509.
      Citations: 199     Fields:    Translation:HumansCells
    68. Tsao AS, Liu S, Fujimoto J, Wistuba II, Lee JJ, Marom EM, Charnsangavej C, Fossella FV, Tran HT, Blumenschein GR, Papadimitrakopoulou V, Kies MS, Hong WK, Stewart DJ. Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. J Thorac Oncol. 2011 Dec; 6(12):2104-11. PMID: 21892101.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    69. Poh CF, Durham JS, Brasher PM, Anderson DW, Berean KW, MacAulay CE, Lee JJ, Rosin MP. Canadian Optically-guided approach for Oral Lesions Surgical (COOLS) trial: study protocol for a randomized controlled trial. BMC Cancer. 2011 Oct 25; 11:462. PMID: 22026481; PMCID: PMC3226575.
      Citations: 13     Fields:    Translation:Humans
    70. Solis LM, Behrens C, Raso MG, Lin HY, Kadara H, Yuan P, Galindo H, Tang X, Lee JJ, Kalhor N, Wistuba II, Moran CA. Histologic patterns and molecular characteristics of lung adenocarcinoma associated with clinical outcome. Cancer. 2012 Jun 01; 118(11):2889-99. PMID: 22020674; PMCID: PMC3369269.
      Citations: 39     Fields:    Translation:Humans
    71. Kim JS, Kim ES, Liu D, Lee JJ, Solis L, Behrens C, Lippman SM, Hong WK, Wistuba II, Lee HY. Prognostic impact of insulin receptor expression on survival of patients with nonsmall cell lung cancer. Cancer. 2012 May 01; 118(9):2454-65. PMID: 21952750; PMCID: PMC3298843.
      Citations: 42     Fields:    Translation:Humans
    72. Sabichi AL, Lee JJ, Grossman HB, Liu S, Richmond E, Czerniak BA, De la Cerda J, Eagle C, Viner JL, Palmer JL, Lerner SP. A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer. Cancer Prev Res (Phila). 2011 Oct; 4(10):1580-9. PMID: 21881030; PMCID: PMC4028708.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    73. Janku F, Lee JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Luthra R, Garrido-Laguna I, Kurzrock R. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One. 2011; 6(7):e22769. PMID: 21829508; PMCID: PMC3146490.
      Citations: 104     Fields:    Translation:Humans
    74. Gold KA, Kim ES, Lee JJ, Wistuba II, Farhangfar CJ, Hong WK. The BATTLE to personalize lung cancer prevention through reverse migration. Cancer Prev Res (Phila). 2011 Jul; 4(7):962-72. PMID: 21733820; PMCID: PMC3171137.
      Citations: 27     Fields:    Translation:Humans
    75. Yang F, Tang X, Riquelme E, Behrens C, Nilsson MB, Giri U, Varella-Garcia M, Byers LA, Lin HY, Wang J, Raso MG, Girard L, Coombes K, Lee JJ, Herbst RS, Minna JD, Heymach JV, Wistuba II. Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy. Cancer Res. 2011 Aug 15; 71(16):5512-21. PMID: 21724587; PMCID: PMC3159530.
      Citations: 29     Fields:    Translation:Humans
    76. Chen YJ, Huang WC, Wei YL, Hsu SC, Yuan P, Lin HY, Wistuba II, Lee JJ, Yen CJ, Su WC, Chang KY, Chang WC, Chou TC, Chou CK, Tsai CH, Hung MC. Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells. PLoS One. 2011; 6(6):e21428. PMID: 21731744; PMCID: PMC3121773.
      Citations: 37     Fields:    Translation:HumansAnimalsCells
    77. Kim ES, Lee JJ, Wistuba II. Cotargeting cyclin D1 starts a new chapter in lung cancer prevention and therapy. Cancer Prev Res (Phila). 2011 Jun; 4(6):779-82. PMID: 21636543.
      Citations: 10     Fields:    Translation:HumansAnimals
    78. Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR, Tsao A, Stewart DJ, Hicks ME, Erasmus J, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, Heymach JV, Mao L, Fossella F, Kies MS, Papadimitrakopoulou V, Davis SE, Lippman SM, Hong WK. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011 Jun; 1(1):44-53. PMID: 22586319; PMCID: PMC4211116.
      Citations: 329     Fields:    Translation:HumansCTClinical Trials
    79. Tsao AS, Wei W, Kuhn E, Spencer L, Solis LM, Suraokar M, Lee JJ, Hong WK, Wistuba II. Immunohistochemical overexpression of platelet-derived growth factor receptor-beta (PDGFR-?) is associated with PDGFRB gene copy number gain in sarcomatoid non-small-cell lung cancer. Clin Lung Cancer. 2011 Nov; 12(6):369-74. PMID: 21729646; PMCID: PMC3643693.
      Citations: 13     Fields:    Translation:Humans
    80. Kim WY, Kim MJ, Moon H, Yuan P, Kim JS, Woo JK, Zhang G, Suh YA, Feng L, Behrens C, Van Pelt CS, Kang H, Lee JJ, Hong WK, Wistuba II, Lee HY. Differential impacts of insulin-like growth factor-binding protein-3 (IGFBP-3) in epithelial IGF-induced lung cancer development. Endocrinology. 2011 Jun; 152(6):2164-73. PMID: 21447628; PMCID: PMC3100627.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    81. William WN, Kim JS, Liu DD, Solis L, Behrens C, Lee JJ, Lippman SM, Kim ES, Hong WK, Wistuba II, Lee HY. The impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival. Ann Oncol. 2012 Jan; 23(1):78-85. PMID: 21430184; PMCID: PMC3276321.
      Citations: 25     Fields:    Translation:HumansCells
    82. Jiffar T, Yilmaz T, Lee J, Hanna E, El-Naggar A, Yu D, Myers JN, Kupferman ME. KiSS1 mediates platinum sensitivity and metastasis suppression in head and neck squamous cell carcinoma. Oncogene. 2011 Jul 14; 30(28):3163-73. PMID: 21383688; PMCID: PMC3136629.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    83. Moeller BJ, Yordy JS, Williams MD, Giri U, Raju U, Molkentine DP, Byers LA, Heymach JV, Story MD, Lee JJ, Sturgis EM, Weber RS, Garden AS, Ang KK, Schwartz DL. DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapy. Clin Cancer Res. 2011 Apr 01; 17(7):2035-43. PMID: 21349997; PMCID: PMC3092475.
      Citations: 40     Fields:    Translation:HumansCells
    84. Lee JJ, Wu X, Hildebrandt MA, Yang H, Khuri FR, Kim E, Gu J, Ye Y, Lotan R, Spitz MR, Hong WK. Global assessment of genetic variation influencing response to retinoid chemoprevention in head and neck cancer patients. Cancer Prev Res (Phila). 2011 Feb; 4(2):185-93. PMID: 21292633; PMCID: PMC3955084.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    85. Saintigny P, Zhang L, Fan YH, El-Naggar AK, Papadimitrakopoulou VA, Feng L, Lee JJ, Kim ES, Ki Hong W, Mao L. Gene expression profiling predicts the development of oral cancer. Cancer Prev Res (Phila). 2011 Feb; 4(2):218-29. PMID: 21292635; PMCID: PMC3074595.
      Citations: 53     Fields:    Translation:Humans
    86. Tang X, Kadara H, Behrens C, Liu DD, Xiao Y, Rice D, Gazdar AF, Fujimoto J, Moran C, Varella-Garcia M, Lee JJ, Hong WK, Wistuba II. Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosis. Clin Cancer Res. 2011 Apr 15; 17(8):2434-43. PMID: 21257719; PMCID: PMC3078948.
      Citations: 42     Fields:    Translation:Humans
    87. Kadara H, Behrens C, Yuan P, Solis L, Liu D, Gu X, Minna JD, Lee JJ, Kim E, Hong WK, Wistuba II, Lotan R. A five-gene and corresponding protein signature for stage-I lung adenocarcinoma prognosis. Clin Cancer Res. 2011 Mar 15; 17(6):1490-501. PMID: 21163870; PMCID: PMC3079395.
      Citations: 38     Fields:    Translation:Humans
    88. Lee JJ. Demystify statistical significance--time to move on from the p value to bayesian analysis. J Natl Cancer Inst. 2011 Jan 05; 103(1):2-3. PMID: 21131578.
      Citations: 6     Fields:    Translation:Humans
    89. Roblyer D, Kurachi C, Stepanek V, Schwarz RA, Williams MD, El-Naggar AK, Lee JJ, Gillenwater AM, Richards-Kortum R. Comparison of multispectral wide-field optical imaging modalities to maximize image contrast for objective discrimination of oral neoplasia. J Biomed Opt. 2010 Nov-Dec; 15(6):066017. PMID: 21198191; PMCID: PMC3013151.
      Citations: 9     Fields:    Translation:Humans
    90. Zhang X, Yang H, Lee JJ, Kim E, Lippman SM, Khuri FR, Spitz MR, Lotan R, Hong WK, Wu X. MicroRNA-related genetic variations as predictors for risk of second primary tumor and/or recurrence in patients with early-stage head and neck cancer. Carcinogenesis. 2010 Dec; 31(12):2118-23. PMID: 20819778; PMCID: PMC3105587.
      Citations: 24     Fields:    Translation:Humans
    91. Fujimoto J, Kong M, Lee JJ, Hong WK, Lotan R. Validation of a novel statistical model for assessing the synergy of combined-agent cancer chemoprevention. Cancer Prev Res (Phila). 2010 Aug; 3(8):917-28. PMID: 20663979; PMCID: PMC3496745.
      Citations: 1     Fields:    Translation:HumansCells
    92. Wang J, Lippman SM, Lee JJ, Yang H, Khuri FR, Kim E, Lin J, Chang DW, Lotan R, Hong WK, Wu X. Genetic variations in regulator of G-protein signaling genes as susceptibility loci for second primary tumor/recurrence in head and neck squamous cell carcinoma. Carcinogenesis. 2010 Oct; 31(10):1755-61. PMID: 20627871; PMCID: PMC2950933.
      Citations: 8     Fields:    Translation:Humans
    93. Lee JJ. Bayesian adaptive randomization designs for targeted agent development. Clin Trials. 2010 Oct; 7(5):584-96. PMID: 20571130; PMCID: PMC5110207.
      Citations: 38     Fields:    Translation:Humans
    94. Taoudi Benchekroun M, Saintigny P, Thomas SM, El-Naggar AK, Papadimitrakopoulou V, Ren H, Lang W, Fan YH, Huang J, Feng L, Lee JJ, Kim ES, Hong WK, Johnson FM, Grandis JR, Mao L. Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. Cancer Prev Res (Phila). 2010 Jul; 3(7):800-9. PMID: 20570883; PMCID: PMC2900459.
      Citations: 44     Fields:    Translation:Humans
    95. Byers LA, Holsinger FC, Kies MS, William WN, El-Naggar AK, Lee JJ, Hu J, Lopez A, Tran HT, Yan S, Du Z, Ang KK, Glisson BS, Raso MG, Wistuba II, Myers JN, Hong WK, Papadimitrakopoulou V, Lippman SM, Heymach JV. Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Mol Cancer Ther. 2010 Jun; 9(6):1755-63. PMID: 20530716; PMCID: PMC2913168.
      Citations: 24     Fields:    Translation:HumansCells
    96. Gu X, Lee JJ. A simulation study for comparing testing statistics in response-adaptive randomization. BMC Med Res Methodol. 2010 Jun 05; 10:48. PMID: 20525382; PMCID: PMC2911470.
      Citations: 7     Fields:    Translation:Humans
    97. Lu C, Lee JJ, Komaki R, Herbst RS, Feng L, Evans WK, Choy H, Desjardins P, Esparaz BT, Truong MT, Saxman S, Kelaghan J, Bleyer A, Fisch MJ. Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial. J Natl Cancer Inst. 2010 Jun 16; 102(12):859-65. PMID: 20505152; PMCID: PMC2902826.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    98. Lee JJ, Feng L, Reshef DS, Sabichi AL, Williams B, Rinsurongkawong W, Wistuba II, Lotan R, Lippman SM. Mortality in the randomized, controlled lung intergroup trial of isotretinoin. Cancer Prev Res (Phila). 2010 Jun; 3(6):738-44. PMID: 20501862; PMCID: PMC2881192.
      Citations: 2     Fields:    Translation:Humans
    99. William WN, Kies MS, Fossella FV, Liu DD, Gladish G, Tse WH, Lee JJ, Hong WK, Lippman SM, Kim ES. Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer. Cancer. 2010 May 15; 116(10):2401-8. PMID: 20225327; PMCID: PMC5145307.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    100. William WN, Khuri FR, Fossella FV, Glisson BS, Zinner RG, Lee JJ, Herbst RS, Lippman SM, Kim ES. Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung cancer as frontline and second-line therapy. Am J Clin Oncol. 2010 Apr; 33(2):148-52. PMID: 19687727; PMCID: PMC5118944.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    101. Moeller BJ, Rana V, Cannon BA, Williams MD, Sturgis EM, Ginsberg LE, Macapinlac HA, Lee JJ, Ang KK, Chao KS, Chronowski GM, Frank SJ, Morrison WH, Rosenthal DI, Weber RS, Garden AS, Lippman SM, Schwartz DL. Prospective imaging assessment of mortality risk after head-and-neck radiotherapy. Int J Radiat Oncol Biol Phys. 2010 Nov 01; 78(3):667-74. PMID: 20171802; PMCID: PMC3072063.
      Citations: 11     Fields:    Translation:HumansCells
    102. Xu L, Nilsson MB, Saintigny P, Cascone T, Herynk MH, Du Z, Nikolinakos PG, Yang Y, Prudkin L, Liu D, Lee JJ, Johnson FM, Wong KK, Girard L, Gazdar AF, Minna JD, Kurie JM, Wistuba II, Heymach JV. Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells. Oncogene. 2010 May 06; 29(18):2616-27. PMID: 20154724; PMCID: PMC3378055.
      Citations: 42     Fields:    Translation:HumansAnimalsCells
    103. Jain RK, Lee JJ, Hong D, Markman M, Gong J, Naing A, Wheler J, Kurzrock R. Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res. 2010 Feb 15; 16(4):1289-97. PMID: 20145187; PMCID: PMC2822881.
      Citations: 45     Fields:    Translation:Humans
    104. Clague J, Lippman SM, Yang H, Hildebrandt MA, Ye Y, Lee JJ, Wu X. Genetic variation in MicroRNA genes and risk of oral premalignant lesions. Mol Carcinog. 2010 Feb; 49(2):183-9. PMID: 19851984; PMCID: PMC3640857.
      Citations: 47     Fields:    Translation:Humans
    105. Kim ES, Hong WK, Lee JJ, Mao L, Morice RC, Liu DD, Jimenez CA, Eapen GA, Lotan R, Tang X, Newman RA, Wistuba II, Kurie JM. Biological activity of celecoxib in the bronchial epithelium of current and former smokers. Cancer Prev Res (Phila). 2010 Feb; 3(2):148-59. PMID: 20103722; PMCID: PMC4028718.
      Citations: 29     Fields:    Translation:Humans
    106. Lee JJ, Lin HY, Liu DD, Kong M. Emax model and interaction index for assessing drug interaction in combination studies. Front Biosci (Elite Ed). 2010 01 01; 2(2):582-601. PMID: 20036904; PMCID: PMC2974574.
      Citations: 2     Fields:    
    107. Kong M, Lee JJ. Applying Emax model and bivariate thin plate splines to assess drug interactions. Front Biosci (Elite Ed). 2010 01 01; 2(1):279-92. PMID: 20036878; PMCID: PMC4203317.
      Citations: 2     Fields:    Translation:HumansCells
    108. Behrens C, Feng L, Kadara H, Kim HJ, Lee JJ, Mehran R, Hong WK, Lotan R, Wistuba II. Expression of interleukin-1 receptor-associated kinase-1 in non-small cell lung carcinoma and preneoplastic lesions. Clin Cancer Res. 2010 Jan 01; 16(1):34-44. PMID: 20028769; PMCID: PMC2811365.
      Citations: 19     Fields:    Translation:HumansCells
    109. Hanrahan EO, Lin HY, Kim ES, Yan S, Du DZ, McKee KS, Tran HT, Lee JJ, Ryan AJ, Langmuir P, Johnson BE, Heymach JV. Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol. 2010 Jan 10; 28(2):193-201. PMID: 19949019; PMCID: PMC3040010.
      Citations: 71     Fields:    Translation:HumansCTClinical Trials
    110. Kies MS, Holsinger FC, Lee JJ, William WN, Glisson BS, Lin HY, Lewin JS, Ginsberg LE, Gillaspy KA, Massarelli E, Byers L, Lippman SM, Hong WK, El-Naggar AK, Garden AS, Papadimitrakopoulou V. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol. 2010 Jan 01; 28(1):8-14. PMID: 19917840; PMCID: PMC2799235.
      Citations: 65     Fields:    Translation:HumansCellsCTClinical Trials
    111. Tsao AS, Liu D, Martin J, Tang XM, Lee JJ, El-Naggar AK, Wistuba I, Culotta KS, Mao L, Gillenwater A, Sagesaka YM, Hong WK, Papadimitrakopoulou V. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila). 2009 Nov; 2(11):931-41. PMID: 19892663; PMCID: PMC4243312.
      Citations: 82     Fields:    Translation:HumansCTClinical Trials
    112. Saintigny P, El-Naggar AK, Papadimitrakopoulou V, Ren H, Fan YH, Feng L, Lee JJ, Kim ES, Hong WK, Lippman SM, Mao L. DeltaNp63 overexpression, alone and in combination with other biomarkers, predicts the development of oral cancer in patients with leukoplakia. Clin Cancer Res. 2009 Oct 01; 15(19):6284-91. PMID: 19773378; PMCID: PMC2756317.
      Citations: 25     Fields:    Translation:HumansCells
    113. Kim WY, Jin Q, Oh SH, Kim ES, Yang YJ, Lee DH, Feng L, Behrens C, Prudkin L, Miller YE, Lee JJ, Lippman SM, Hong WK, Wistuba II, Lee HY. Elevated epithelial insulin-like growth factor expression is a risk factor for lung cancer development. Cancer Res. 2009 Sep 15; 69(18):7439-48. PMID: 19738076; PMCID: PMC2745504.
      Citations: 33     Fields:    Translation:HumansAnimals
    114. Raso MG, Behrens C, Herynk MH, Liu S, Prudkin L, Ozburn NC, Woods DM, Tang X, Mehran RJ, Moran C, Lee JJ, Wistuba II. Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res. 2009 Sep 01; 15(17):5359-68. PMID: 19706809; PMCID: PMC2893045.
      Citations: 77     Fields:    Translation:HumansCells
    115. Kadara H, Lacroix L, Behrens C, Solis L, Gu X, Lee JJ, Tahara E, Lotan D, Hong WK, Wistuba II, Lotan R. Identification of gene signatures and molecular markers for human lung cancer prognosis using an in vitro lung carcinogenesis system. Cancer Prev Res (Phila). 2009 Aug; 2(8):702-11. PMID: 19638491; PMCID: PMC3382104.
      Citations: 31     Fields:    Translation:HumansCells
    116. Wang M, Delasalle K, Feng L, Thomas S, Giralt S, Qazilbash M, Handy B, Lee JJ, Alexanian R. CR represents an early index of potential long survival in multiple myeloma. Bone Marrow Transplant. 2010 Mar; 45(3):498-504. PMID: 19633690; PMCID: PMC5777472.
      Citations: 22     Fields:    Translation:Humans
    117. Zhang J, Liu B, Jiang X, Zhao H, Fan M, Fan Z, Lee JJ, Jiang T, Jiang T, Song SW. A systems biology-based gene expression classifier of glioblastoma predicts survival with solid tumors. PLoS One. 2009 Jul 17; 4(7):e6274. PMID: 19609451; PMCID: PMC2707631.
      Citations: 12     Fields:    Translation:Humans
    118. Wu X, Spitz MR, Lee JJ, Lippman SM, Ye Y, Yang H, Khuri FR, Kim E, Gu J, Lotan R, Hong WK. Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants. Cancer Prev Res (Phila). 2009 Jul; 2(7):617-24. PMID: 19584075; PMCID: PMC2964280.
      Citations: 39     Fields:    Translation:Humans
    119. Biswas S, Liu DD, Lee JJ, Berry DA. Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center. Clin Trials. 2009 Jun; 6(3):205-16. PMID: 19528130; PMCID: PMC2913209.
      Citations: 32     Fields:    Translation:Humans
    120. Lambert LA, Armstrong TS, Lee JJ, Liu S, Katz MH, Eng C, Wolff RA, Tortorice ML, Tansey P, Gonzalez-Moreno S, Lambert DH, Mansfield PF. Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C. Ann Surg Oncol. 2009 Aug; 16(8):2181-7. PMID: 19475451; PMCID: PMC2711905.
      Citations: 21     Fields:    Translation:Humans
    121. Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst. 2009 May 20; 101(10):708-20. PMID: 19436029; PMCID: PMC2684552.
      Citations: 268     Fields:    Translation:HumansCTClinical Trials
    122. Roblyer D, Kurachi C, Stepanek V, Williams MD, El-Naggar AK, Lee JJ, Gillenwater AM, Richards-Kortum R. Objective detection and delineation of oral neoplasia using autofluorescence imaging. Cancer Prev Res (Phila). 2009 May; 2(5):423-31. PMID: 19401530; PMCID: PMC2719708.
      Citations: 59     Fields:    Translation:HumansPHPublic Health
    123. Schwarz RA, Gao W, Redden Weber C, Kurachi C, Lee JJ, El-Naggar AK, Richards-Kortum R, Gillenwater AM. Noninvasive evaluation of oral lesions using depth-sensitive optical spectroscopy. Cancer. 2009 Apr 15; 115(8):1669-79. PMID: 19170229; PMCID: PMC2728679.
      Citations: 43     Fields:    Translation:Humans
    124. Kim ES, Mauer AM, William WN, Tran HT, Liu D, Lee JJ, Windt P, Hong WK, Vokes EE, Herbst RS. A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer. Cancer. 2009 Apr 15; 115(8):1713-22. PMID: 19208430; PMCID: PMC5142442.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    125. Kajiwara Y, Panchabhai S, Liu DD, Kong M, Lee JJ, Levin VA. Melding a New 3-Dimensional Agarose Colony Assay with the E(max) Model to Determine the Effects of Drug Combinations on Cancer Cells. Technol Cancer Res Treat. 2009 Apr; 8(2):163-76. PMID: 19334798; PMCID: PMC5481785.
      Citations: 2     Fields:    Translation:HumansCells
    126. Pu X, Lippman SM, Yang H, Lee JJ, Wu X. Cyclooxygenase-2 gene polymorphisms reduce the risk of oral premalignant lesions. Cancer. 2009 Apr 01; 115(7):1498-506. PMID: 19197984; PMCID: PMC2666299.
      Citations: 10     Fields:    Translation:Humans
    127. Moeller BJ, Rana V, Cannon BA, Williams MD, Sturgis EM, Ginsberg LE, Macapinlac HA, Lee JJ, Ang KK, Chao KS, Chronowski GM, Frank SJ, Morrison WH, Rosenthal DI, Weber RS, Garden AS, Lippman SM, Schwartz DL. Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. J Clin Oncol. 2009 May 20; 27(15):2509-15. PMID: 19332725; PMCID: PMC2739610.
      Citations: 59     Fields:    Translation:HumansCTClinical Trials
    128. William WN, Lin HY, Lee JJ, Lippman SM, Roth JA, Kim ES. Revisiting stage IIIB and IV non-small cell lung cancer: analysis of the surveillance, epidemiology, and end results data. Chest. 2009 Sep; 136(3):701-709. PMID: 19318668.
      Citations: 42     Fields:    Translation:Humans
    129. Holsinger FC, Kies MS, Diaz EM, Gillenwater AM, Lewin JS, Ginsberg LE, Glisson BS, Garden AS, Ark N, Lin HY, Lee JJ, El-Naggar AK, Ki Hong W, Shin DM, Khuri FR. Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer. J Clin Oncol. 2009 Apr 20; 27(12):1976-82. PMID: 19289628; PMCID: PMC2738635.
      Citations: 13     Fields:    Translation:Humans
    130. William WN, Lee JL, Shin DM, Hong WK, Liu S, Lee JJ, Lippman SM, Khuri FR, Kim ES. Phase I trial of weekly topotecan and gemcitabine in patients with solid tumors. Am J Clin Oncol. 2009 Feb; 32(1):15-9. PMID: 19194117; PMCID: PMC5120668.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    131. Lee JJ, Kong M. Confidence Intervals of Interaction Index for Assessing Multiple Drug Interaction. Stat Biopharm Res. 2009 Feb 01; 1(1):4-17. PMID: 20037663; PMCID: PMC2796809.
      Citations: 14     
    132. Papadimitrakopoulou V, Izzo JG, Liu DD, Myers J, Ceron TL, Lewin J, William WN, Atwell A, Lee JJ, Gillenwater A, El-Naggar A, Wu X, Lippman SM, Hittelman WN, Hong WK. Cyclin D1 and cancer development in laryngeal premalignancy patients. Cancer Prev Res (Phila). 2009 Jan; 2(1):14-21. PMID: 19139013; PMCID: PMC4243520.
      Citations: 12     Fields:    Translation:Humans
    133. William WN, Lee JJ, Lippman SM, Martin JW, Chakravarti N, Tran HT, Sabichi AL, Kim ES, Feng L, Lotan R, Papadimitrakopoulou VA. High-dose fenretinide in oral leukoplakia. Cancer Prev Res (Phila). 2009 Jan; 2(1):22-6. PMID: 19139014; PMCID: PMC4161148.
      Citations: 20     Fields:    Translation:HumansCellsCTClinical Trials
    134. Papadimitrakopoulou VA, Lee JJ, William WN, Martin JW, Thomas M, Kim ES, Khuri FR, Shin DM, Feng L, Hong WK, Lippman SM. Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. J Clin Oncol. 2009 Feb 01; 27(4):599-604. PMID: 19075276; PMCID: PMC2645856.
      Citations: 39     Fields:    Translation:Humans
    135. Ye Y, Lippman SM, Lee JJ, Chen M, Frazier ML, Spitz MR, Wu X. Genetic variations in cell-cycle pathway and the risk of oral premalignant lesions. Cancer. 2008 Nov 01; 113(9):2488-95. PMID: 18823025; PMCID: PMC2577230.
      Citations: 6     Fields:    Translation:Humans
    136. Behrens C, Lin HY, Lee JJ, Raso MG, Hong WK, Wistuba II, Lotan R. Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer. Clin Cancer Res. 2008 Oct 01; 14(19):6014-22. PMID: 18829480; PMCID: PMC5108626.
      Citations: 50     Fields:    Translation:Humans
    137. Yang H, Lippman SM, Huang M, Jack Lee J, Wang W, Spitz MR, Wu X. Genetic polymorphisms in double-strand break DNA repair genes associated with risk of oral premalignant lesions. Eur J Cancer. 2008 Jul; 44(11):1603-11. PMID: 18579371; PMCID: PMC2603619.
      Citations: 13     Fields:    Translation:HumansCells
    138. Bhutani M, Pathak AK, Fan YH, Liu DD, Lee JJ, Tang H, Kurie JM, Morice RC, Kim ES, Hong WK, Mao L. Oral epithelium as a surrogate tissue for assessing smoking-induced molecular alterations in the lungs. Cancer Prev Res (Phila). 2008 Jun; 1(1):39-44. PMID: 19138934; PMCID: PMC4183362.
      Citations: 31     Fields:    Translation:HumansCells
    139. Papadimitrakopoulou VA, William WN, Dannenberg AJ, Lippman SM, Lee JJ, Ondrey FG, Peterson DE, Feng L, Atwell A, El-Naggar AK, Nathan CO, Helman JI, Du B, Yueh B, Boyle JO. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res. 2008 Apr 01; 14(7):2095-101. PMID: 18381950.
      Citations: 40     Fields:    Translation:HumansCTClinical Trials
    140. Zhang L, Lee JJ, Tang H, Fan YH, Xiao L, Ren H, Kurie J, Morice RC, Hong WK, Mao L. Impact of smoking cessation on global gene expression in the bronchial epithelium of chronic smokers. Cancer Prev Res (Phila). 2008 Jul; 1(2):112-8. PMID: 19138944; PMCID: PMC4181408.
      Citations: 35     Fields:    Translation:Humans
    141. Svatek RS, Lee JJ, Roehrborn CG, Lippman SM, Lotan Y. Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis. Cancer. 2008 Mar 01; 112(5):1058-65. PMID: 18186497.
      Citations: 21     Fields:    Translation:Humans
    142. Kawaguchi H, El-Naggar AK, Papadimitrakopoulou V, Ren H, Fan YH, Feng L, Lee JJ, Kim E, Hong WK, Lippman SM, Mao L. Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol. 2008 Jan 20; 26(3):354-60. PMID: 18202409.
      Citations: 69     Fields:    Translation:HumansCells
    143. Zhou X, Liu S, Kim ES, Herbst RS, Lee JJ. Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine. Clin Trials. 2008; 5(3):181-93. PMID: 18559407; PMCID: PMC5481999.
      Citations: 63     Fields:    Translation:Humans
    144. Lee JJ, Liu DD. A predictive probability design for phase II cancer clinical trials. Clin Trials. 2008; 5(2):93-106. PMID: 18375647; PMCID: PMC5626665.
      Citations: 36     Fields:    Translation:Humans
    145. Tao Q, Fujimoto J, Men T, Ye X, Deng J, Lacroix L, Clifford JL, Mao L, Van Pelt CS, Lee JJ, Lotan D, Lotan R. Identification of the retinoic acid-inducible Gprc5a as a new lung tumor suppressor gene. J Natl Cancer Inst. 2007 Nov 21; 99(22):1668-82. PMID: 18000218.
      Citations: 52     Fields:    Translation:HumansAnimalsCells
    146. Wang LE, Li C, Strom SS, Goldberg LH, Brewster A, Guo Z, Qiao Y, Clayman GL, Lee JJ, El-Naggar AK, Prieto VG, Duvic M, Lippman SM, Weber RS, Kripke ML, Wei Q. Repair capacity for UV light induced DNA damage associated with risk of nonmelanoma skin cancer and tumor progression. Clin Cancer Res. 2007 Nov 01; 13(21):6532-9. PMID: 17975167.
      Citations: 22     Fields:    Translation:HumansCells
    147. Hittelman WN, Liu DD, Kurie JM, Lotan R, Lee JS, Khuri F, Ibarguen H, Morice RC, Walsh G, Roth JA, Minna J, Ro JY, Broxson A, Hong WK, Lee JJ. Proliferative changes in the bronchial epithelium of former smokers treated with retinoids. J Natl Cancer Inst. 2007 Nov 07; 99(21):1603-12. PMID: 17971525; PMCID: PMC3441140.
      Citations: 10     Fields:    Translation:Humans
    148. Kong M, Lee JJ. A semiparametric response surface model for assessing drug interaction. Biometrics. 2008 Jun; 64(2):396-405. PMID: 17900314; PMCID: PMC5096313.
      Citations: 12     Fields:    
    149. Tsao AS, He D, Saigal B, Liu S, Lee JJ, Bakkannagari S, Ordonez NG, Hong WK, Wistuba I, Johnson FM. Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther. 2007 Jul; 6(7):1962-72. PMID: 17620427.
      Citations: 45     Fields:    Translation:HumansCells
    150. Wang Y, Spitz MR, Lee JJ, Huang M, Lippman SM, Wu X. Nucleotide excision repair pathway genes and oral premalignant lesions. Clin Cancer Res. 2007 Jun 15; 13(12):3753-8. PMID: 17575242.
      Citations: 33     Fields:    Translation:HumansCells
    151. Temam S, Kawaguchi H, El-Naggar AK, Jelinek J, Tang H, Liu DD, Lang W, Issa JP, Lee JJ, Mao L. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol. 2007 Jun 01; 25(16):2164-70. PMID: 17538160.
      Citations: 139     Fields:    Translation:Humans
    152. Brewster AM, Lee JJ, Clayman GL, Clifford JL, Reyes MJ, Zhou X, Sabichi AL, Strom SS, Collins R, Meyers CA, Lippman SM. Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma. J Clin Oncol. 2007 May 20; 25(15):1974-8. PMID: 17513803.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    153. Lee JJ, Kong M, Ayers GD, Lotan R. Interaction index and different methods for determining drug interaction in combination therapy. J Biopharm Stat. 2007; 17(3):461-80. PMID: 17479394.
      Citations: 56     Fields:    Translation:HumansAnimalsCells
    154. Shen J, Behrens C, Wistuba II, Feng L, Lee JJ, Hong WK, Lotan R. Identification and validation of differences in protein levels in normal, premalignant, and malignant lung cells and tissues using high-throughput Western Array and immunohistochemistry. Cancer Res. 2006 Dec 01; 66(23):11194-206. PMID: 17145864.
      Citations: 26     Fields:    Translation:HumansCells
    155. Kong M, Lee JJ. A generalized response surface model with varying relative potency for assessing drug interaction. Biometrics. 2006 Dec; 62(4):986-95. PMID: 17156272.
      Citations: 18     Fields:    Translation:HumansCells
    156. Tang X, Liu D, Shishodia S, Ozburn N, Behrens C, Lee JJ, Hong WK, Aggarwal BB, Wistuba II. Nuclear factor-kappaB (NF-kappaB) is frequently expressed in lung cancer and preneoplastic lesions. Cancer. 2006 Dec 01; 107(11):2637-46. PMID: 17078054.
      Citations: 75     Fields:    Translation:Humans
    157. Wang J, Walsh G, Liu DD, Lee JJ, Mao L. Expression of Delta DNMT3B variants and its association with promoter methylation of p16 and RASSF1A in primary non-small cell lung cancer. Cancer Res. 2006 Sep 01; 66(17):8361-6. PMID: 16951144.
      Citations: 30     Fields:    Translation:HumansCells
    158. Tsao AS, Garden AS, Kies MS, Morrison W, Feng L, Lee JJ, Khuri F, Zinner R, Myers J, Papadimitrakopoulou V, Lewin J, Clayman GL, Ang KK, Glisson BS. Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. J Clin Oncol. 2006 Sep 01; 24(25):4163-9. PMID: 16943532.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    159. Lee JJ, Bekele BN, Zhou X, Cantor SB, Komaki R, Lee JS. Decision analysis for prophylactic cranial irradiation for patients with small-cell lung cancer. J Clin Oncol. 2006 Aug 01; 24(22):3597-603. PMID: 16877726.
      Citations: 13     Fields:    Translation:Humans
    160. Svatek RS, Lee JJ, Roehrborn CG, Lippman SM, Lotan Y. The cost of prostate cancer chemoprevention: a decision analysis model. Cancer Epidemiol Biomarkers Prev. 2006 Aug; 15(8):1485-9. PMID: 16896037.
      Citations: 13     Fields:    Translation:Humans
    161. Yuan P, Temam S, El-Naggar A, Zhou X, Liu DD, Lee JJ, Mao L. Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer. 2006 Aug 01; 107(3):563-9. PMID: 16804930.
      Citations: 106     Fields:    Translation:HumansCells
    162. Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ, Szabo E, Jordan VC, Spitz MR, Mills GB, Papadimitrakopoulou VA, Lotan R, Aggarwal BB, Bresalier RS, Kim J, Arun B, Lu KH, Thomas ME, Rhodes HE, Brewer MA, Follen M, Shin DM, Parnes HL, Siegfried JM, Evans AA, Blot WJ, Chow WH, Blount PL, Maley CC, Wang KK, Lam S, Lee JJ, Dubinett SM, Engstrom PF, Meyskens FL, O'Shaughnessy J, Hawk ET, Levin B, Nelson WG, Hong WK, AACR Task Force on Cancer Prevention. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res. 2006 Jun 15; 12(12):3661-97. PMID: 16778094.
      Citations: 88     Fields:    Translation:HumansCells
    163. Tsao AS, Liu D, Lee JJ, Spitz M, Hong WK. Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer. Cancer. 2006 Jun 01; 106(11):2428-36. PMID: 16634096.
      Citations: 51     Fields:    Translation:Humans
    164. Lippman SM, Lee JJ, Martin JW, El-Naggar AK, Xu X, Shin DM, Thomas M, Mao L, Fritsche HA, Zhou X, Papadimitrakopoulou V, Khuri FR, Tran H, Clayman GL, Hittelman WN, Hong WK, Lotan R. Fenretinide activity in retinoid-resistant oral leukoplakia. Clin Cancer Res. 2006 May 15; 12(10):3109-14. PMID: 16707609.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    165. Huang M, Spitz MR, Gu J, Lee JJ, Lin J, Lippman SM, Wu X. Cyclin D1 gene polymorphism as a risk factor for oral premalignant lesions. Carcinogenesis. 2006 Oct; 27(10):2034-7. PMID: 16638786.
      Citations: 22     Fields:    Translation:Humans
    166. Khuri FR, Lee JJ, Lippman SM, Kim ES, Cooper JS, Benner SE, Winn R, Pajak TF, Williams B, Shenouda G, Hodson I, Fu K, Shin DM, Vokes EE, Feng L, Goepfert H, Hong WK. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst. 2006 Apr 05; 98(7):441-50. PMID: 16595780.
      Citations: 86     Fields:    Translation:HumansCTClinical Trials
    167. Sabichi AL, Lee JJ, Taylor RJ, Thompson IM, Miles BJ, Tangen CM, Minasian LM, Pisters LL, Caton JR, Basler JW, Lerner SP, Menter DG, Marshall JR, Crawford ED, Lippman SM. Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study. Clin Cancer Res. 2006 Apr 01; 12(7 Pt 1):2178-84. PMID: 16609032.
      Citations: 15     Fields:    Translation:Humans
    168. Lippman SM, Lee JJ. Reducing the "risk" of chemoprevention: defining and targeting high risk--2005 AACR Cancer Research and Prevention Foundation Award Lecture. Cancer Res. 2006 Mar 15; 66(6):2893-903. PMID: 16540634.
      Citations: 10     Fields:    Translation:Humans
    169. Thomas SK, Fossella FV, Liu D, Schaerer R, Tsao AS, Kies MS, Pisters KM, Blumenschein GR, Glisson BS, Lee JJ, Herbst RS, Zinner RG. Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. Clin Lung Cancer. 2006 Mar; 7(5):326-31. PMID: 16640804.
      Citations: 8     Fields:    Translation:Humans
    170. Massarelli E, Liu DD, Lee JJ, El-Naggar AK, Lo Muzio L, Staibano S, De Placido S, Myers JN, Papadimitrakopoulou VA. Akt activation correlates with adverse outcome in tongue cancer. Cancer. 2005 Dec 01; 104(11):2430-6. PMID: 16245318.
      Citations: 42     Fields:    Translation:HumansCells
    171. Lee JJ, Lippman SM, Mork J, Sagen S, Flatner N, Mao L, Zhou X, Kildal W, Evensen JF, Reith A, Dannenberg AJ, Sudb? J, Ristim?ki A, Sudb? A. Non-steroidal anti-inflammatory drugs and the risk of oral cancer: a nested case-control study. Lancet. 2005 Oct 15-21; 366(9494):1359-66. PMID: 16226613.
      Citations: 11     Fields:    Translation:Humans
    172. Papadimitrakopoulou VA, Brown EN, Liu DD, El-Naggar AK, Jack Lee J, Hong WK, Lee HY. The prognostic role of loss of insulin-like growth factor-binding protein-3 expression in head and neck carcinogenesis. Cancer Lett. 2006 Jul 28; 239(1):136-43. PMID: 16181731.
      Citations: 20     Fields:    Translation:HumansCells
    173. Moore BA, Weber RS, Prieto V, El-Naggar A, Holsinger FC, Zhou X, Lee JJ, Lippman S, Clayman GL. Lymph node metastases from cutaneous squamous cell carcinoma of the head and neck. Laryngoscope. 2005 Sep; 115(9):1561-7. PMID: 16148695.
      Citations: 49     Fields:    Translation:Humans
    174. Lee HY, Chang YS, Han JY, Liu DD, Lee JJ, Lotan R, Spitz MR, Hong WK. Effects of 9-cis-retinoic acid on the insulin-like growth factor axis in former smokers. J Clin Oncol. 2005 Jul 01; 23(19):4439-49. PMID: 15994153.
      Citations: 4     Fields:    Translation:Humans
    175. Lee JJ, Feng L. Randomized phase II designs in cancer clinical trials: current status and future directions. J Clin Oncol. 2005 Jul 01; 23(19):4450-7. PMID: 15994154.
      Citations: 36     Fields:    Translation:Humans
    176. Xu XC, Lee JJ, Wu TT, Hoque A, Ajani JA, Lippman SM. Increased retinoic acid receptor-beta4 correlates in vivo with reduced retinoic acid receptor-beta2 in esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2005 Apr; 14(4):826-9. PMID: 15824151.
      Citations: 5     Fields:    Translation:Humans
    177. Ewart-Toland A, Dai Q, Gao YT, Nagase H, Dunlop MG, Farrington SM, Barnetson RA, Anton-Culver H, Peel D, Ziogas A, Lin D, Miao X, Sun T, Ostrander EA, Stanford JL, Langlois M, Chan JM, Yuan J, Harris CC, Bowman ED, Clayman GL, Lippman SM, Lee JJ, Zheng W, Balmain A. Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. Carcinogenesis. 2005 Aug; 26(8):1368-73. PMID: 15802297.
      Citations: 48     Fields:    Translation:HumansAnimals
    178. Lotan Y, Cadeddu JA, Lee JJ, Roehrborn CG, Lippman SM. Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes. J Clin Oncol. 2005 Mar 20; 23(9):1911-20. PMID: 15774783.
      Citations: 7     Fields:    Translation:Humans
    179. Han JY, Liu DD, Lee JJ, Kurie J, Lotan R, Hong WK, Lee HY. 9-cis-retinoic acid treatment increases serum concentrations of alpha-tocopherol in former smokers. Clin Cancer Res. 2005 Mar 15; 11(6):2305-11. PMID: 15788681.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    180. Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein G, Lee JJ, Liu DD, Truong MT, Hong WK, Tran H, Tsao A, Xie D, Ramies DA, Mass R, Seshagiri S, Eberhard DA, Kelley SK, Sandler A. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005 Apr 10; 23(11):2544-55. PMID: 15753462.
      Citations: 130     Fields:    Translation:HumansCTClinical Trials
    181. Massarelli E, Brown E, Tran NK, Liu DD, Izzo JG, Lee JJ, El-Naggar AK, Hong WK, Papadimitrakopoulou VA. Loss of E-cadherin and p27 expression is associated with head and neck squamous tumorigenesis. Cancer. 2005 Mar 01; 103(5):952-9. PMID: 15666322.
      Citations: 9     Fields:    Translation:Humans
    182. Clayman GL, Lee JJ, Holsinger FC, Zhou X, Duvic M, El-Naggar AK, Prieto VG, Altamirano E, Tucker SL, Strom SS, Kripke ML, Lippman SM. Mortality risk from squamous cell skin cancer. J Clin Oncol. 2005 Feb 01; 23(4):759-65. PMID: 15681519.
      Citations: 67     Fields:    Translation:Humans
    183. Do KA, Johnson MM, Lee JJ, Wu XF, Dong Q, Hong WK, Khuri FR, Spitz MR. Longitudinal study of smoking patterns in relation to the development of smoking-related secondary primary tumors in patients with upper aerodigestive tract malignancies. Cancer. 2004 Dec 15; 101(12):2837-42. PMID: 15536619.
      Citations: 34     Fields:    Translation:Humans
    184. Wang CC, Juang LC, Lee CK, Hsu TC, Lee JF, Chao HP. Effects of exchanged surfactant cations on the pore structure and adsorption characteristics of montmorillonite. J Colloid Interface Sci. 2004 Dec 01; 280(1):27-35. PMID: 15476770.
      Citations: 6     Fields:    
    185. Wang J, Lee JJ, Wang L, Liu DD, Lu C, Fan YH, Hong WK, Mao L. Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer. Clin Cancer Res. 2004 Sep 15; 10(18 Pt 1):6119-25. PMID: 15447998.
      Citations: 25     Fields:    Translation:HumansCells
    186. Ren H, Tang X, Lee JJ, Feng L, Everett AD, Hong WK, Khuri FR, Mao L. Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer. J Clin Oncol. 2004 Aug 15; 22(16):3230-7. PMID: 15310766.
      Citations: 48     Fields:    Translation:Humans
    187. Tai SK, Lee JI, Ang KK, El-Naggar AK, Hassan KA, Liu D, Lee JJ, Ren H, Hong WK, Mao L. Loss of Fhit expression in head and neck squamous cell carcinoma and its potential clinical implication. Clin Cancer Res. 2004 Aug 15; 10(16):5554-7. PMID: 15328196.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    188. Maruya S, Kim HW, Weber RS, Lee JJ, Kies M, Luna MA, Batsakis JG, El-Naggar AK. Gene expression screening of salivary gland neoplasms: molecular markers of potential histogenetic and clinical significance. J Mol Diagn. 2004 Aug; 6(3):180-90. PMID: 15269293; PMCID: PMC1867638.
      Citations: 17     Fields:    Translation:HumansCells
    189. Clinical targeting of VEGF and EGFR effective in non-small cell lung cancer. Cancer Biol Ther. 2004 Jul; 3(7):588-9. PMID: 15751163.
      Citations:    Fields:    Translation:Humans
    190. Temam S, Casiraghi O, Lahaye JB, Bosq J, Zhou X, Julieron M, Mamelle G, Lee JJ, Mao L, Luboinski B, Benard J, Janot F. Tetranucleotide microsatellite instability in surgical margins for prediction of local recurrence of head and neck squamous cell carcinoma. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 1):4022-8. PMID: 15217934.
      Citations: 8     Fields:    Translation:HumansCells
    191. Wang CC, Juang LC, Hsu TC, Lee CK, Lee JF, Huang FC. Adsorption of basic dyes onto montmorillonite. J Colloid Interface Sci. 2004 May 01; 273(1):80-6. PMID: 15051435.
      Citations: 8     Fields:    
    192. Lippman SM, Lee JJ, Mao L, Kildal W, Sagen S, Bryne M, El-Naggar A, Evensen JF, Reith A, Sudb? J, Sudb? A, Risberg B. The influence of resection and aneuploidy on mortality in oral leukoplakia. N Engl J Med. 2004 Apr 01; 350(14):1405-13. PMID: 15070790.
      Citations: 12     Fields:    Translation:Humans
    193. Youssef EM, Lotan D, Issa JP, Wakasa K, Fan YH, Mao L, Hassan K, Feng L, Lee JJ, Lippman SM, Hong WK, Lotan R. Hypermethylation of the retinoic acid receptor-beta(2) gene in head and neck carcinogenesis. Clin Cancer Res. 2004 Mar 01; 10(5):1733-42. PMID: 15014026.
      Citations: 41     Fields:    Translation:HumansCells
    194. Rice D, Kim HW, Sabichi A, Lippman S, Lee JJ, Williams B, Vaporciyan A, Smythe WR, Swisher S, Walsh G, Putnam JB, Hong WK, Roth J. The risk of second primary tumors after resection of stage I nonsmall cell lung cancer. Ann Thorac Surg. 2003 Oct; 76(4):1001-7; discussion 1007-8. PMID: 14529975.
      Citations: 38     Fields:    Translation:HumansCTClinical Trials
    195. Moon H, Ahn H, Kodell RL, Lee JJ. Estimation of k for the poly-k test with application to animal carcinogenicity studies. Stat Med. 2003 Aug 30; 22(16):2619-36. PMID: 12898548.
      Citations: 1     Fields:    Translation:Animals
    196. Sabichi AL, Modiano MR, Lee JJ, Peng YM, Xu MJ, Villar H, Dalton WS, Lippman SM. Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide. Clin Cancer Res. 2003 Jul; 9(7):2400-5. PMID: 12855611.
      Citations: 10     Fields:    Translation:Humans
    197. Johnson FM, Kurie JM, Peeples BO, Lee JJ, Feng L, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer. Clin Lung Cancer. 2003 Jul; 5(1):40-5. PMID: 14596703.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    198. Do KA, Johnson MM, Doherty DA, Lee JJ, Wu XF, Dong Q, Hong WK, Khuri FR, Fu KK, Spitz MR. Second primary tumors in patients with upper aerodigestive tract cancers: joint effects of smoking and alcohol (United States). Cancer Causes Control. 2003 Mar; 14(2):131-8. PMID: 12749718.
      Citations: 57     Fields:    Translation:HumansCTClinical Trials
    199. Izzo JG, Papadimitrakopoulou VA, Liu DD, den Hollander PL, Babenko IM, Keck J, El-Naggar AK, Shin DM, Lee JJ, Hong WK, Hittelman WN. Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer. J Natl Cancer Inst. 2003 Feb 05; 95(3):198-205. PMID: 12569141.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    200. Kurie JM, Lotan R, Lee JJ, Lee JS, Morice RC, Liu DD, Xu XC, Khuri FR, Ro JY, Hittelman WN, Walsh GL, Roth JA, Minna JD, Hong WK. Treatment of former smokers with 9-cis-retinoic acid reverses loss of retinoic acid receptor-beta expression in the bronchial epithelium: results from a randomized placebo-controlled trial. J Natl Cancer Inst. 2003 Feb 05; 95(3):206-14. PMID: 12569142.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    201. Soria JC, Xu X, Liu DD, Lee JJ, Kurie J, Morice RC, Khuri F, Mao L, Hong WK, Lotan R. Retinoic acid receptor beta and telomerase catalytic subunit expression in bronchial epithelium of heavy smokers. J Natl Cancer Inst. 2003 Jan 15; 95(2):165-8. PMID: 12529350.
      Citations: 6     Fields:    Translation:HumansCells
    202. Swisher SG, Roth JA, Komaki R, Gu J, Lee JJ, Hicks M, Ro JY, Hong WK, Merritt JA, Ahrar K, Atkinson NE, Correa AM, Dolormente M, Dreiling L, El-Naggar AK, Fossella F, Francisco R, Glisson B, Grammer S, Herbst R, Huaringa A, Kemp B, Khuri FR, Kurie JM, Liao Z, McDonnell TJ, Morice R, Morello F, Munden R, Papadimitrakopoulou V, Pisters KM, Putnam JB, Sarabia AJ, Shelton T, Stevens C, Shin DM, Smythe WR, Vaporciyan AA, Walsh GL, Yin M. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res. 2003 Jan; 9(1):93-101. PMID: 12538456.
      Citations: 47     Fields:    Translation:HumansCellsCTClinical Trials
    203. Massarelli E, Andre F, Liu DD, Lee JJ, Wolf M, Fandi A, Ochs J, Le Chevalier T, Fossella F, Herbst RS. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer. 2003 Jan; 39(1):55-61. PMID: 12499095.
      Citations: 50     Fields:    Translation:Humans
    204. Papadimitrakopoulou VA, Liu DD, Mao L, Shin DM, El-Naggar A, Ibarguen H, Lee JJ, Hong WK, Hittelman WN. Biologic correlates of a biochemoprevention trial in advanced upper aerodigestive tract premalignant lesions. Cancer Epidemiol Biomarkers Prev. 2002 Dec; 11(12):1605-10. PMID: 12496051.
      Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
    205. El-Naggar AK, Kim HW, Clayman GL, Coombes MM, Le B, Lai S, Zhan F, Luna MA, Hong WK, Lee JJ. Differential expression profiling of head and neck squamous carcinoma: significance in their phenotypic and biological classification. Oncogene. 2002 Nov 21; 21(53):8206-19. PMID: 12444558.
      Citations: 16     Fields:    Translation:Humans
    206. Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, von Eschenbach AC, Kuban DA, Rosen I. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002 Aug 01; 53(5):1097-105. PMID: 12128107.
      Citations: 287     Fields:    Translation:HumansCTClinical Trials
    207. Herbst RS, Khuri FR, Lu C, Liu DD, Fossella FV, Glisson BS, Pisters KM, Shin DM, Papadimitrakopoulou VA, Kurie JM, Blumenschein G, Kies MS, Zinner R, Jung MS, Lu R, Lee JJ, Munden RF, Hong WK, Lee JS. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy. Cancer. 2002 Jul 15; 95(2):340-53. PMID: 12124835.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    208. Wu X, Lippman SM, Lee JJ, Zhu Y, Wei QV, Thomas M, Hong WK, Spitz MR. Chromosome instability in lymphocytes: a potential indicator of predisposition to oral premalignant lesions. Cancer Res. 2002 May 15; 62(10):2813-8. PMID: 12019158.
      Citations: 8     Fields:    Translation:HumansCells
    209. Eton O, Legha SS, Bedikian AY, Lee JJ, Buzaid AC, Hodges C, Ring SE, Papadopoulos NE, Plager C, East MJ, Zhan F, Benjamin RS. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol. 2002 Apr 15; 20(8):2045-52. PMID: 11956264.
      Citations: 68     Fields:    Translation:HumansCTClinical Trials
    210. Shureiqi I, Jiang W, Fischer SM, Xu X, Chen D, Lee JJ, Lotan R, Lippman SM. GATA-6 transcriptional regulation of 15-lipoxygenase-1 during NSAID-induced apoptosis in colorectal cancer cells. Cancer Res. 2002 Feb 15; 62(4):1178-83. PMID: 11861401.
      Citations: 15     Fields:    Translation:HumansCells
    211. Shin DM, Glisson BS, Khuri FR, Clifford JL, Clayman G, Benner SE, Forastiere AA, Ginsberg L, Liu D, Lee JJ, Myers J, Goepfert H, Lotan R, Hong WK, Lippman SM. Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. J Clin Oncol. 2002 Jan 15; 20(2):364-70. PMID: 11786562.
      Citations: 33     Fields:    Translation:HumansCellsCTClinical Trials
    212. Soria JC, Rodriguez M, Liu DD, Lee JJ, Hong WK, Mao L. Aberrant promoter methylation of multiple genes in bronchial brush samples from former cigarette smokers. Cancer Res. 2002 Jan 15; 62(2):351-5. PMID: 11809677.
      Citations: 32     Fields:    Translation:HumansCells
    213. Soria JC, Moon C, Wang L, Hittelman WN, Jang SJ, Sun SY, Lee JJ, Liu D, Kurie JM, Morice RC, Lee JS, Hong WK, Mao L. Effects of N-(4-hydroxyphenyl)retinamide on hTERT expression in the bronchial epithelium of cigarette smokers. J Natl Cancer Inst. 2001 Aug 15; 93(16):1257-63. PMID: 11504771.
      Citations: 8     Fields:    Translation:HumansCellsCTClinical Trials
    214. Khuri FR, Kim ES, Lee JJ, Winn RJ, Benner SE, Lippman SM, Fu KK, Cooper JS, Vokes EE, Chamberlain RM, Williams B, Pajak TF, Goepfert H, Hong WK. The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. Cancer Epidemiol Biomarkers Prev. 2001 Aug; 10(8):823-9. PMID: 11489748.
      Citations: 71     Fields:    Translation:HumansCTClinical Trials
    215. Lee JJ, Liu D, Lee JS, Kurie JM, Khuri FR, Ibarguen H, Morice RC, Walsh G, Ro JY, Broxson A, Hong WK, Hittelman WN. Long-term impact of smoking on lung epithelial proliferation in current and former smokers. J Natl Cancer Inst. 2001 Jul 18; 93(14):1081-8. PMID: 11459869.
      Citations: 34     Fields:    Translation:HumansCells
    216. Shin DM, Charuruks N, Lippman SM, Lee JJ, Ro JY, Hong WK, Hittelman WN. p53 protein accumulation and genomic instability in head and neck multistep tumorigenesis. Cancer Epidemiol Biomarkers Prev. 2001 Jun; 10(6):603-9. PMID: 11401909.
      Citations: 14     Fields:    Translation:HumansCells
    217. Lippman SM, Lee JJ, Karp DD, Vokes EE, Benner SE, Goodman GE, Khuri FR, Marks R, Winn RJ, Fry W, Graziano SL, Gandara DR, Okawara G, Woodhouse CL, Williams B, Perez C, Kim HW, Lotan R, Roth JA, Hong WK. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst. 2001 Apr 18; 93(8):605-18. PMID: 11309437.
      Citations: 59     Fields:    Translation:HumansCTClinical Trials
    218. Khuri FR, Wu H, Lee JJ, Kemp BL, Lotan R, Lippman SM, Feng L, Hong WK, Xu XC. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res. 2001 Apr; 7(4):861-7. PMID: 11309334.
      Citations: 100     Fields:    Translation:Humans
    219. Khuri FR, Lee JS, Lippman SM, Lee JJ, Kalapurakal S, Yu R, Ro JY, Morice RC, Hong WK, Hittelman WN. Modulation of proliferating cell nuclear antigen in the bronchial epithelium of smokers. Cancer Epidemiol Biomarkers Prev. 2001 Apr; 10(4):311-8. PMID: 11319170.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    220. Lee JJ, Lieberman R, Sloan JA, Piantadosi S, Lippman SM. Design considerations for efficient prostate cancer chemoprevention trials. Urology. 2001 Apr; 57(4 Suppl 1):205-12. PMID: 11295629.
      Citations: 5     Fields:    Translation:Humans
    221. Lieberman R, Nelson WG, Sakr WA, Meyskens FL, Klein EA, Wilding G, Partin AW, Lee JJ, Lippman SM. Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations. Urology. 2001 Apr; 57(4 Suppl 1):4-27. PMID: 11295590.
      Citations: 2     Fields:    Translation:Humans
    222. Royce ME, Hoff PM, Dumas P, Lassere Y, Lee JJ, Coyle J, Ducharme MP, De Jager R, Pazdur R. Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog. J Clin Oncol. 2001 Mar 01; 19(5):1493-500. PMID: 11230496.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    223. Pollack A, Zagars GK, Smith LG, Lee JJ, von Eschenbach AC, Antolak JA, Starkschall G, Rosen I. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol. 2000 Dec 01; 18(23):3904-11. PMID: 11099319.
      Citations: 94     Fields:    Translation:HumansCTClinical Trials
    224. Grimm EA, Smid CM, Lee JJ, Tseng CH, Eton O, Buzaid AC. Unexpected cytokines in serum of malignant melanoma patients during sequential biochemotherapy. Clin Cancer Res. 2000 Oct; 6(10):3895-903. PMID: 11051235.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    225. Tang X, Khuri FR, Lee JJ, Kemp BL, Liu D, Hong WK, Mao L. Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J Natl Cancer Inst. 2000 Sep 20; 92(18):1511-6. PMID: 10995806.
      Citations: 47     Fields:    Translation:HumansCells
    226. Khuri FR, Lotan R, Kemp BL, Lippman SM, Wu H, Feng L, Lee JJ, Cooksley CS, Parr B, Chang E, Walsh GL, Lee JS, Hong WK, Xu XC. Retinoic acid receptor-beta as a prognostic indicator in stage I non-small-cell lung cancer. J Clin Oncol. 2000 Aug; 18(15):2798-804. PMID: 10920126.
      Citations: 17     Fields:    Translation:Humans
    227. Kurie JM, Lee JS, Khuri FR, Mao L, Morice RC, Lee JJ, Walsh GL, Broxson A, Lippman SM, Ro JY, Kemp BL, Liu D, Fritsche HA, Xu X, Lotan R, Hong WK. N-(4-hydroxyphenyl)retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium. Clin Cancer Res. 2000 Aug; 6(8):2973-9. PMID: 10955773.
      Citations: 19     Fields:    Translation:HumansCellsCTClinical Trials
    228. Shureiqi I, Chen D, Lee JJ, Yang P, Newman RA, Brenner DE, Lotan R, Fischer SM, Lippman SM. 15-LOX-1: a novel molecular target of nonsteroidal anti-inflammatory drug-induced apoptosis in colorectal cancer cells. J Natl Cancer Inst. 2000 Jul 19; 92(14):1136-42. PMID: 10904086.
      Citations: 50     Fields:    Translation:HumansCells
    229. Tae K, El-Naggar AK, Yoo E, Feng L, Lee JJ, Hong WK, Hittelman WN, Shin DM. Expression of vascular endothelial growth factor and microvessel density in head and neck tumorigenesis. Clin Cancer Res. 2000 Jul; 6(7):2821-8. PMID: 10914730.
      Citations: 39     Fields:    Translation:Humans
    230. Lee JJ, Hong WK, Hittelman WN, Mao L, Lotan R, Shin DM, Benner SE, Xu XC, Lee JS, Papadimitrakopoulou VM, Geyer C, Perez C, Martin JW, El-Naggar AK, Lippman SM. Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res. 2000 May; 6(5):1702-10. PMID: 10815888.
      Citations: 112     Fields:    Translation:HumansCells
    231. Yen N, Ioannides CG, Xu K, Swisher SG, Lawrence DD, Kemp BL, El-Naggar AK, Cristiano RJ, Fang B, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Merritt JA, Mukhopadhyay T, Nesbitt JC, Nguyen D, Perez-Soler R, Pisters KM, Putnam JB, Schrump DS, Shin DM, Walsh GL, Roth JA. Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type. P53 (Ad-p53). Cancer Gene Ther. 2000 Apr; 7(4):530-6. PMID: 10811470.
      Citations: 8     Fields:    Translation:HumansCellsCTClinical Trials
    232. Herbst RS, Yano S, Kuniyasu H, Khuri FR, Bucana CD, Guo F, Liu D, Kemp B, Lee JJ, Hong WK, Fidler IJ. Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma. Clin Cancer Res. 2000 Mar; 6(3):790-7. PMID: 10741698.
      Citations: 12     Fields:    Translation:Humans
    233. Nemunaitis J, Swisher SG, Timmons T, Connors D, Mack M, Doerksen L, Weill D, Wait J, Lawrence DD, Kemp BL, Fossella F, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JJ, Lee JS, Nguyen DM, Nesbitt JC, Perez-Soler R, Pisters KM, Putnam JB, Richli WR, Shin DM, Walsh GL, Merritt J, Roth J. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol. 2000 Feb; 18(3):609-22. PMID: 10653876.
      Citations: 43     Fields:    Translation:HumansCellsCTClinical Trials
    234. Zhou X, Kemp BL, Khuri FR, Liu D, Lee JJ, Wu W, Hong WK, Mao L. Prognostic implication of microsatellite alteration profiles in early-stage non-small cell lung cancer. Clin Cancer Res. 2000 Feb; 6(2):559-65. PMID: 10690539.
      Citations: 11     Fields:    Translation:HumansCells
    235. Shin DM, Mao L, Papadimitrakopoulou VM, Clayman G, El-Naggar A, Shin HJ, Lee JJ, Lee JS, Gillenwater A, Myers J, Lippman SM, Hittelman WN, Hong WK. Biochemopreventive therapy for patients with premalignant lesions of the head and neck and p53 gene expression. J Natl Cancer Inst. 2000 Jan 05; 92(1):69-73. PMID: 10620636.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    236. Gershenson DM, Morris M, Burke TW, Levenback C, Wolf J, Lee JJ, Thall PF, Atkinson EN, Silva EG, Wharton JT. A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma. Cancer. 1999 Dec 01; 86(11):2291-300. PMID: 10590370.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    237. Ellerhorst J, Troncoso P, Xu XC, Lee J, Lotan R. Galectin-1 and galectin-3 expression in human prostate tissue and prostate cancer. Urol Res. 1999 Oct; 27(5):362-7. PMID: 10550525.
      Citations: 30     Fields:    Translation:Humans
    238. Xu XC, Lee JS, Lee JJ, Morice RC, Liu X, Lippman SM, Hong WK, Lotan R. Nuclear retinoid acid receptor beta in bronchial epithelium of smokers before and during chemoprevention. J Natl Cancer Inst. 1999 Aug 04; 91(15):1317-21. PMID: 10433621.
      Citations: 9     Fields:    Translation:HumansCellsCTClinical Trials
    239. Thall PF, Lee JJ, Tseng CH, Estey EH. Accrual strategies for phase I trials with delayed patient outcome. Stat Med. 1999 May 30; 18(10):1155-69. PMID: 10363337.
      Citations: 11     Fields:    Translation:Humans
    240. Swisher SG, Roth JA, Nemunaitis J, Lawrence DD, Kemp BL, Carrasco CH, Connors DG, El-Naggar AK, Fossella F, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Mack M, Merritt JA, Nguyen DM, Nesbitt JC, Perez-Soler R, Pisters KM, Putnam JB, Richli WR, Savin M, Schrump DS, Shin DM, Shulkin A, Walsh GL, Wait J, Weill D, Waugh MK. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst. 1999 May 05; 91(9):763-71. PMID: 10328106.
      Citations: 50     Fields:    Translation:HumansCellsCTClinical Trials
    241. Meyskens FL. Re: Cancer chemoprevention: progress and promise. J Natl Cancer Inst. 1999 Mar 17; 91(6):563-5. PMID: 10088631.
      Citations:    Fields:    Translation:Humans
    242. Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Lee JE, Colome MI, Tseng CH, Lee JJ, Balch CM, Reintgen DS, Ross MI. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol. 1999 Mar; 17(3):976-83. PMID: 10071292.
      Citations: 152     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    243. Colome M, Bedikian A, Eton O, Legha SS, Papadopoulos N, Plager C, Ross M, Lee JE, Mansfield P, Rice J, Ring S, Lee JJ, Strom E, Benjamin R, Buzaid AC. Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases. Melanoma Res. 1998 Dec; 8(6):549-56. PMID: 9918417.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    244. Lippman SM, Lee JJ, Sabichi AL. Cancer chemoprevention: progress and promise. J Natl Cancer Inst. 1998 Oct 21; 90(20):1514-28. PMID: 9790544.
      Citations: 19     Fields:    Translation:Humans
    245. Mao L, El-Naggar AK, Papadimitrakopoulou V, Shin DM, Shin HC, Fan Y, Zhou X, Clayman G, Lee JJ, Lee JS, Hittelman WN, Lippman SM, Hong WK. Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. J Natl Cancer Inst. 1998 Oct 21; 90(20):1545-51. PMID: 9790547.
      Citations: 25     Fields:    Translation:HumansCells
    246. Wu X, Gu J, Hong WK, Lee JJ, Amos CI, Jiang H, Winn RJ, Fu KK, Cooper J, Spitz MR. Benzo[a]pyrene diol epoxide and bleomycin sensitivity and susceptibility to cancer of upper aerodigestive tract. J Natl Cancer Inst. 1998 Sep 16; 90(18):1393-9. PMID: 9747870.
      Citations: 8     Fields:    Translation:HumansCells
    247. Gershenwald JE, Tseng CH, Thompson W, Mansfield PF, Lee JE, Bouvet M, Lee JJ, Ross MI. Improved sentinel lymph node localization in patients with primary melanoma with the use of radiolabeled colloid. Surgery. 1998 Aug; 124(2):203-10. PMID: 9706139.
      Citations: 20     Fields:    Translation:Humans
    248. Zhou J, Mulshine JL, Ro JY, Avis I, Yu R, Lee JJ, Morice R, Lippman SM, Lee JS. Expression of heterogeneous nuclear ribonucleoprotein A2/B1 in bronchial epithelium of chronic smokers. Clin Cancer Res. 1998 Jul; 4(7):1631-40. PMID: 9676837.
      Citations: 5     Fields:    Translation:HumansCellsCTClinical Trials
    249. Gershenwald JE, Colome MI, Lee JE, Lee JE, Mansfield PF, Tseng C, Lee JJ, Balch CM, Ross MI. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol. 1998 Jun; 16(6):2253-60. PMID: 9626228.
      Citations: 67     Fields:    Translation:Humans
    250. Bouvet M, Ellis LM, Nishizaki M, Fujiwara T, Liu W, Bucana CD, Fang B, Lee JJ, Roth JA. Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res. 1998 Jun 01; 58(11):2288-92. PMID: 9622060.
      Citations: 44     Fields:    Translation:HumansCells
    251. Buzaid AC, Ali-Osman F, Akande N, Grimm EA, Lee JJ, Bedikian A, Eton O, Papadopoulos N, Plager C, Legha SS, Benjamin RS. DNA damage in peripheral blood mononuclear cells correlates with response to biochemotherapy in melanoma. Melanoma Res. 1998 Apr; 8(2):145-8. PMID: 9610867.
      Citations:    Fields:    Translation:HumansCellsCTClinical Trials
    252. Shin DM, Glisson BS, Khuri FR, Ginsberg L, Papadimitrakopoulou V, Lee JJ, Lawhorn K, Gillenwater AM, Ang KK, Clayman GL, Callender DL, Hong WK, Lippman SM. Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J Clin Oncol. 1998 Apr; 16(4):1325-30. PMID: 9552033.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    253. Anderson CM, Buzaid AC, Sussman J, Lee JJ, Ali-Osman F, Braunschweiger PG, Plager C, Bedikian A, Papadopoulos N, Eton O, Legha SS, Grimm EA. Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapy. Melanoma Res. 1998 Apr; 8(2):149-55. PMID: 9610868.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    254. Spitz MR, Lippman SM, Jiang H, Lee JJ, Khuri F, Hsu TC, Trizna Z, Schantz SP, Benner S, Hong WK. Mutagen sensitivity as a predictor of tumor recurrence in patients with cancer of the upper aerodigestive tract. J Natl Cancer Inst. 1998 Feb 04; 90(3):243-5. PMID: 9462683.
      Citations: 1     Fields:    Translation:Humans
    255. Mitchell MF, Tortolero-Luna G, Lee JJ, Hittelman WN, Lotan R, Wharton JT, Hong WK, Nishioka K. Phase I dose de-escalation trial of alpha-difluoromethylornithine in patients with grade 3 cervical intraepithelial neoplasia. Clin Cancer Res. 1998 Feb; 4(2):303-10. PMID: 9516915.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    256. Wu X, Hsu TC, Cao S, Lee JJ, Amos CI, Spitz MR. Deletion in poly(ADP-ribose)polymerase pseudogene and lung cancer risk. Carcinogenesis. 1998 Jan; 19(1):93-8. PMID: 9472699.
      Citations: 1     Fields:    Translation:HumansCells
    257. Park TK, Lee JP, Kim SN, Choi SM, Kudelka AP, Kavanagh JJ. Interferon-alpha 2a, 13-cis-retinoic acid and radiotherapy for locally advanced carcinoma of the cervix: a pilot study. Eur J Gynaecol Oncol. 1998; 19(1):35-8. PMID: 9476056.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    258. El-Naggar AK, Lai S, Clayman G, Lee JK, Luna MA, Goepfert H, Batsakis JG. Methylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous carcinoma. Am J Pathol. 1997 Dec; 151(6):1767-74. PMID: 9403727; PMCID: PMC1858347.
      Citations: 32     Fields:    Translation:HumansCells
    259. Xu XC, Sneige N, Liu X, Nandagiri R, Lee JJ, Lukmanji F, Hortobagyi G, Lippman SM, Dhingra K, Lotan R. Progressive decrease in nuclear retinoic acid receptor beta messenger RNA level during breast carcinogenesis. Cancer Res. 1997 Nov 15; 57(22):4992-6. PMID: 9371489.
      Citations: 25     Fields:    Translation:Humans
    260. Spitz MR, McPherson RS, Jiang H, Hsu TC, Trizna Z, Lee JJ, Lippman SM, Khuri FR, Steffen-Batey L, Chamberlain RM, Schantz SP, Hong WK. Correlates of mutagen sensitivity in patients with upper aerodigestive tract cancer. Cancer Epidemiol Biomarkers Prev. 1997 Sep; 6(9):687-92. PMID: 9298575.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    261. Jung FA, Buzaid AC, Ross MI, Woods KV, Lee JJ, Albitar M, Grimm EA. Evaluation of tyrosinase mRNA as a tumor marker in the blood of melanoma patients. J Clin Oncol. 1997 Aug; 15(8):2826-31. PMID: 9256125.
      Citations: 15     Fields:    Translation:HumansCells
    262. Konishi H, Steinbach G, Terry NH, Fujita K, Lee JJ, Ruifrok A, Spaulding D, Lynch PM, Dubin JA, Andreeff M, Goodacre AM, Hattori T, Hittelman WN. S phase determination in intact colonic crypts by histone H3 messenger RNA in situ hybridization and confocal microscopy. Cancer Epidemiol Biomarkers Prev. 1997 Jul; 6(7):531-6. PMID: 9232341.
      Citations: 1     Fields:    Translation:AnimalsCells
    263. Mao L, Lee JS, Kurie JM, Fan YH, Lippman SM, Lee JJ, Ro JY, Broxson A, Yu R, Morice RC, Kemp BL, Khuri FR, Walsh GL, Hittelman WN, Hong WK. Clonal genetic alterations in the lungs of current and former smokers. J Natl Cancer Inst. 1997 Jun 18; 89(12):857-62. PMID: 9196251.
      Citations: 82     Fields:    Translation:HumansCells
    264. Shin DM, Xu XC, Lippman SM, Lee JJ, Lee JS, Batsakis JG, Ro JY, Martin JW, Hittelman WN, Lotan R, Hong WK. Accumulation of p53 protein and retinoic acid receptor beta in retinoid chemoprevention. Clin Cancer Res. 1997 Jun; 3(6):875-80. PMID: 9815762.
      Citations: 9     Fields:    Translation:HumansCells
    265. Xu XC, Sozzi G, Lee JS, Lee JJ, Pastorino U, Pilotti S, Kurie JM, Hong WK, Lotan R. Suppression of retinoic acid receptor beta in non-small-cell lung cancer in vivo: implications for lung cancer development. J Natl Cancer Inst. 1997 May 07; 89(9):624-9. PMID: 9150186.
      Citations: 36     Fields:    Translation:HumansCells
    266. Papadimitrakopoulou VA, Dimery IW, Lee JJ, Perez C, Hong WK, Lippman SM. Cisplatin, fluorouracil, and L-leucovorin induction chemotherapy for locally advanced head and neck cancer: the M.D. Anderson Cancer Center experience. Cancer J Sci Am. 1997 Mar-Apr; 3(2):92-9. PMID: 9099459.
      Citations:    Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    267. Shin HJ, Kalapurakal SK, Lee JJ, Ro JY, Hong WK, Lee JS. Comparison of p53 immunoreactivity in fresh-cut versus stored slides with and without microwave heating. Mod Pathol. 1997 Mar; 10(3):224-30. PMID: 9071730.
      Citations: 5     Fields:    Translation:Humans
    268. Papadimitrakopoulou VA, Hong WK, Lee JS, Martin JW, Lee JJ, Batsakis JG, Lippman SM. Low-dose isotretinoin versus beta-carotene to prevent oral carcinogenesis: long-term follow-up. J Natl Cancer Inst. 1997 Feb 05; 89(3):257-8. PMID: 9017007.
      Citations: 22     Fields:    Translation:Humans
    269. Dimery IW, Hong WK, Lee JJ, Guillory-Perez C, Pham F, Fritsche HA, Lippman SM. Phase I trial of alpha-tocopherol effects on 13-cis-retinoic acid toxicity. Ann Oncol. 1997 Jan; 8(1):85-9. PMID: 9093712.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    270. Mitchell MF, Tortolero-Luna G, Lee JJ, Hittelman WK, Lotan R, Wharton JT, Hong WK, Nishioka K. Polyamine measurements in the uterine cervix. J Cell Biochem Suppl. 1997; 28-29:125-32. PMID: 9589357.
      Citations: 1     Fields:    Translation:Humans
    271. Konishi H, Steinbach G, Hittelman WN, Fujita K, Lee JJ, Glober GA, Levin B, Andreeff M, Goodacre AM, Terry NH. Cell kinetic analysis of intact rat colonic crypts by confocal microscopy and immunofluorescence. Gastroenterology. 1996 Dec; 111(6):1493-500. PMID: 8942727.
      Citations: 4     Fields:    Translation:AnimalsCells
    272. Sinicrope FA, Evans DB, Leach SD, Cleary KR, Fenoglio CJ, Lee JJ, Abbruzzese JL. bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome. Clin Cancer Res. 1996 Dec; 2(12):2015-22. PMID: 9816161.
      Citations: 12     Fields:    Translation:Humans
    273. Sim SJ, Glassman AB, Ro JY, Lee JJ, Logothetis CJ, Liu FJ. Serum calcitonin in small cell carcinoma of the prostate. Ann Clin Lab Sci. 1996 Nov-Dec; 26(6):487-95. PMID: 8908318.
      Citations: 5     Fields:    Translation:Humans
    274. Kurie JM, Shin HJ, Lee JS, Morice RC, Ro JY, Lippman SM, Hittelman WN, Yu R, Lee JJ, Hong WK. Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium. Clin Cancer Res. 1996 Oct; 2(10):1787-93. PMID: 9816131.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    275. Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, Hong WK, Komaki R, Lee JJ, Nesbitt JC, Pisters KM, Putnam JB, Schea R, Shin DM, Walsh GL, Dolormente MM, Han CI, Martin FD, Yen N, Xu K, Stephens LC, McDonnell TJ, Mukhopadhyay T, Cai D. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med. 1996 Sep; 2(9):985-91. PMID: 8782455.
      Citations: 97     Fields:    Translation:HumansCellsCTClinical Trials
    276. Steinbach G, Lupton J, Reddy BS, Lee JJ, Kral JG, Holt PR. Calcium carbonate treatment of diarrhoea in intestinal bypass patients. Eur J Gastroenterol Hepatol. 1996 Jun; 8(6):559-62. PMID: 8823570.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    277. Shin DM, Lee JS, Lippman SM, Lee JJ, Tu ZN, Choi G, Heyne K, Shin HJ, Ro JY, Goepfert H, Hong WK, Hittelman WN. p53 expressions: predicting recurrence and second primary tumors in head and neck squamous cell carcinoma. J Natl Cancer Inst. 1996 Apr 17; 88(8):519-29. PMID: 8606380.
      Citations: 25     Fields:    Translation:Humans
    278. Perez-Soler R, Fossella FV, Glisson BS, Lee JS, Murphy WK, Shin DM, Kemp BL, Lee JJ, Kane J, Robinson RA, Lippman SM, Kurie JM, Huber MH, Raber MN, Hong WK. Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. J Clin Oncol. 1996 Feb; 14(2):503-13. PMID: 8636764.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    279. Konishi H, Steinbach G, Terry NH, Lee JJ, Dubin JA, Glober GA, Fujita K, Spaulding D, Cass L, Hittelman WN. Histone H3 messenger RNA in situ hybridization correlates with in vivo bromodeoxyuridine labeling of S-phase cells in rat colonic epithelium. Cancer Res. 1996 Feb 01; 56(3):434-7. PMID: 8564947.
      Citations: 3     Fields:    Translation:AnimalsCells
    280. Smith TL, Lee JJ, Kantarjian HM, Legha SS, Raber MN. Design and results of phase I cancer clinical trials: three-year experience at M.D. Anderson Cancer Center. J Clin Oncol. 1996 Jan; 14(1):287-95. PMID: 8558210.
      Citations: 13     Fields:    Translation:Humans
    281. Xu XC, Zile MH, Lippman SM, Lee JS, Lee JJ, Hong WK, Lotan R. Anti-retinoic acid (RA) antibody binding to human premalignant oral lesions, which occurs less frequently than binding to normal tissue, increases after 13-cis-RA treatment in vivo and is related to RA receptor beta expression. Cancer Res. 1995 Dec 01; 55(23):5507-11. PMID: 7585623.
      Citations: 10     Fields:    Translation:Humans
    282. Walsh GL, O'Connor M, Willis KM, Milas M, Wong RS, Nesbitt JC, Putnam JB, Lee JJ, Roth JA. Is follow-up of lung cancer patients after resection medically indicated and cost-effective? Ann Thorac Surg. 1995 Dec; 60(6):1563-70; discussion 1570-2. PMID: 8787445.
      Citations: 35     Fields:    Translation:Humans
    283. Sinicrope FA, Hart J, Michelassi F, Lee JJ. Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma. Clin Cancer Res. 1995 Oct; 1(10):1103-10. PMID: 9815900.
      Citations: 35     Fields:    Translation:Humans
    284. Buzaid AC, Tinoco LA, Jendiroba D, Tu ZN, Lee JJ, Legha SS, Ross MI, Balch CM, Benjamin RS. Prognostic value of size of lymph node metastases in patients with cutaneous melanoma. J Clin Oncol. 1995 Sep; 13(9):2361-8. PMID: 7666095.
      Citations: 3     Fields:    Translation:Humans
    285. Lee JS, Yoon A, Kalapurakal SK, Ro JY, Lee JJ, Tu N, Hittelman WN, Hong WK. Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor. J Clin Oncol. 1995 Aug; 13(8):1893-903. PMID: 7636531.
      Citations: 37     Fields:    Translation:Humans
    286. Lotan R, Xu XC, Lippman SM, Ro JY, Lee JS, Lee JJ, Hong WK. Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. N Engl J Med. 1995 May 25; 332(21):1405-10. PMID: 7723796.
      Citations: 62     Fields:    Translation:HumansCells
    287. Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ, Levin B. bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res. 1995 Jan 15; 55(2):237-41. PMID: 7812951.
      Citations: 167     Fields:    Translation:HumansCells
    288. Clayman GL, Chamberlain RM, Lee JJ, Lippman SM, Hong WK. Screening at a health fair to identify subjects for an oral leukoplakia chemoprevention trial. J Cancer Educ. 1995; 10(2):88-90. PMID: 7669540.
      Citations: 1     Fields:    Translation:Humans
    289. Lippman SM, Shin DM, Lee JJ, Batsakis JG, Lotan R, Tainsky MA, Hittelman WN, Hong WK. p53 and retinoid chemoprevention of oral carcinogenesis. Cancer Res. 1995 Jan 01; 55(1):16-9. PMID: 7805028.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    290. Sinicrope FA, Hart J, Brasitus TA, Michelassi F, Lee JJ, Safa AR. Relationship of P-glycoprotein and carcinoembryonic antigen expression in human colon carcinoma to local invasion, DNA ploidy, and disease relapse. Cancer. 1994 Dec 01; 74(11):2908-17. PMID: 7954255.
      Citations: 12     Fields:    Translation:Humans
    291. Benner SE, Lippman SM, Wargovich MJ, Lee JJ, Velasco M, Martin JW, Toth BB, Hong WK. Micronuclei, a biomarker for chemoprevention trials: results of a randomized study in oral pre-malignancy. Int J Cancer. 1994 Nov 15; 59(4):457-9. PMID: 7960211.
      Citations: 7     Fields:    Translation:HumansCellsCTClinical Trials
    292. Lee JS, Lippman SM, Benner SE, Lee JJ, Ro JY, Lukeman JM, Morice RC, Peters EJ, Pang AC, Fritsche HA, et al. Randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia. J Clin Oncol. 1994 May; 12(5):937-45. PMID: 8164045.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    293. Schag CA, Ganz PA, Wing DS, Sim MS, Lee JJ. Quality of life in adult survivors of lung, colon and prostate cancer. Qual Life Res. 1994 Apr; 3(2):127-41. PMID: 8044158.
      Citations: 76     Fields:    Translation:Humans
    294. Bindal RK, Sawaya R, Leavens ME, Lee JJ. Surgical treatment of multiple brain metastases. J Neurosurg. 1993 Aug; 79(2):210-6. PMID: 8331402.
      Citations: 116     Fields:    Translation:Humans
    295. Dimopoulos MA, Cabanillas F, Lee JJ, Swan F, Fuller L, Allen PK, Hagemeister FB. Prognostic role of serum beta 2-microglobulin in Hodgkin's disease. J Clin Oncol. 1993 Jun; 11(6):1108-11. PMID: 8501496.
      Citations: 9     Fields:    Translation:Humans
    296. Lippman SM, Batsakis JG, Toth BB, Weber RS, Lee JJ, Martin JW, Hays GL, Goepfert H, Hong WK. Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med. 1993 Jan 07; 328(1):15-20. PMID: 8416267.
      Citations: 56     Fields:    Translation:HumansCTClinical Trials
    297. Trizna Z, Schantz SP, Lee JJ, Spitz MR, Goepfert H, Hsu TC, Hong WK. In vitro protective effects of chemopreventive agents against bleomycin-induced genotoxicity in lymphoblastoid cell lines and peripheral blood lymphocytes of head and neck cancer patients. Cancer Detect Prev. 1993; 17(6):575-83. PMID: 7506126.
      Citations:    Fields:    Translation:HumansCells
    298. Heyne KH, Lippman SM, Lee JJ, Lee JS, Hong WK. The incidence of second primary tumors in long-term survivors of small-cell lung cancer. J Clin Oncol. 1992 Oct; 10(10):1519-24. PMID: 1328547.
      Citations: 13     Fields:    Translation:Humans
    299. Ganz PA, Lee JJ, Sim MS, Polinsky ML, Schag CA. Exploring the influence of multiple variables on the relationship of age to quality of life in women with breast cancer. J Clin Epidemiol. 1992 May; 45(5):473-85. PMID: 1588353.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    300. Ganz PA, Schag AC, Lee JJ, Polinsky ML, Tan SJ. Breast conservation versus mastectomy. Is there a difference in psychological adjustment or quality of life in the year after surgery? Cancer. 1992 Apr 01; 69(7):1729-38. PMID: 1551058.
      Citations: 65     Fields:    Translation:HumansCTClinical Trials
    301. Ganz PA, Schag CA, Lee JJ, Sim MS. The CARES: a generic measure of health-related quality of life for patients with cancer. Qual Life Res. 1992 Feb; 1(1):19-29. PMID: 1301111.
      Citations: 47     Fields:    Translation:Humans
    302. Trizna Z, Hsu TC, Schantz SP, Lee JJ, Hong WK. Anticlastogenic effects of 13-cis-retinoic acid in vitro. Eur J Cancer. 1992; 29A(1):137-40. PMID: 1280151.
      Citations:    Fields:    Translation:HumansCells
    303. Lee JJ. A note on the conditional approach to interval estimation in the calibration problem. Biometrics. 1991 Dec; 47(4):1573-80. PMID: 1786330.
      Citations:    Fields:    
    304. Ganz PA, Lee JJ, Siau J. Quality of life assessment. An independent prognostic variable for survival in lung cancer. Cancer. 1991 Jun 15; 67(12):3131-5. PMID: 1710541.
      Citations: 72     Fields:    Translation:Humans
    305. Trujillo JM, Yang LY, Gercovich G, Su YZ, Lee J. Metronidazole enhances the cytotoxic synergism produced by the combination of 1-beta-arabinofuranosylcytosine and cis-diamminedichloroplatinum. Anticancer Res. 1989 Nov-Dec; 9(6):1751-6. PMID: 2627125.
      Citations: 2     Fields:    Translation:HumansCells
    306. Elashoff RM, Lee JJ, Afifi AA. A note on confidence limits for quartiles with right censored data. Stat Med. 1989 Oct; 8(10):1269-76. PMID: 2814074.
      Citations: 1     Fields:    
    307. Gratt BM, Pullinger A, Sickles EA, Lee JJ. Electronic thermography of normal facial structures: a pilot study. Oral Surg Oral Med Oral Pathol. 1989 Sep; 68(3):346-51. PMID: 2771378.
      Citations: 6     Fields:    Translation:Humans
    308. Jacobson JJ, Schweitzer S, DePorter DJ, Lee JJ. Chemoprophylaxis of dental patients with prosthetic joints: a simulation model. J Dent Educ. 1988 Nov; 52(11):599-604. PMID: 3183167.
      Citations: 2     Fields:    Translation:Humans
    309. Afifi AA, Elashoff RM, Lee JJ. Simultaneous non-parametric confidence intervals for survival probabilities from censored data. Stat Med. 1986 Nov-Dec; 5(6):653-62. PMID: 3823672.
      Citations: 3     Fields:    Translation:Humans
    310. Comparison of Bayesian sample size criteria. Journal of Statistical Planning and Inference. 139:4111-4122.
    311. Prediction-Oriented Marker Selection (PROMISE). Statistics in Biosciences. 1-29.
    312. Challenges in initiating and conducting personalized cancer therapy trials. Annals of Oncology. 26:1791-1798.
    313. Cancer Chemoprevention.
    314. Erratum. Gastroenterology. 116:1507.
    315. Frequent expression of MAGE1 tumor antigens in bronchial epithelium of smokers without lung cancer. Experimental and Therapeutic Medicine. 2:137-142.
    316. CD147 and Ki-67 overexpression confers poor prognosis in squamous cell carcinoma of oral tongue. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology.
    317. Response. Journal of the National Cancer Institute. 101:1733-1735.
    318. Changes in hepatic nonhistone chromosomal proteins (NHCP) during carcinogenesis induced by diverse carcinogens. Federation Proceedings. 41.
    319. Statistical Methods for Biomarker Analysis for Head and Neck Carcinogenesis and Prevention. 287-303.
    320. Nonparametric regression analysis of longitudinal data. Journal of the American Statistical Association. 93:1403-1418.
    321. Likelihood-weighted confidence intervals for the difference of two binomial proportions. Biometrical Journal. 39:387-407.
    322. Phase ib randomized, Double-blinded, Placebo- Controlled, Dose escalation study of polyphenon e in patients with barrett's esophagus. Cancer Prevention Research. 8:1131-1137.
    323. Erratum. Journal of the National Cancer Institute. 108.
    324. Monotonic single-index models to assess drug interactions. Statistics in Medicine. 36:655-670.
    325. Adaptive designs for identifying optimal biological dose for molecularly targeted agents. Clinical Trials. 11:319-327.
    326. Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity - Response. Cancer Research. 71:2794-2795.
    327. The ISG15-specific protease USP18 regulates stability of PTEN. Oncotarget. 8:3-14.
    328. New DNA methylation markers and global DNA hypomethylation are associated with oral cancer development. Cancer Prevention Research. 8:1027-1035.
    329. Expression pattern of FGFR2, Grb2 and Plcγ1 acts as a novel prognostic marker of recurrence recurrence-free survival in lung adenocarcinoma. American Journal of Cancer Research. 5:3135-3148.
    330. Erratum. Journal of Thoracic Oncology. 7:1065.
    331. Novel Statistical Models for NSCLC Clinical Trials. 488-504.
    332. Transforming cancer prevention through precision medicine and immune-oncology. Cancer Prevention Research. 9:2-10.
    333. A second-order semiparametric method for survival analysis, with application to an acquired immune deficiency syndrome clinical trial study. Journal of the Royal Statistical Society. Series C: Applied Statistics.
    334. A robust two-stage design identifying the optimal biological dose for phase I/II clinical trials. Statistics in Medicine. 36:27-42.
    335. Polyamine measurements in the uterine cervix. Journal of Cellular Biochemistry. 67:125-132.
    336. Two-stage marker-stratified clinical trial design in the presence of biomarker misclassification. Journal of the Royal Statistical Society. Series C: Applied Statistics. 65:585-601.
    337. The tobacco-specific carcinogen-operated calcium channel promotes lung tumorigenesis via IGF2 exocytosis in lung epithelial cells. Nature Communications. 7.
    338. Evaluation of iopamidol and diatrizoate in excretory urography. Investigative Radiology. 25:1256-1257.
    339. Radiotherapy and Oncology. 120:48-55.
    340. Extensions and applications of event charts. American Statistician. 54:63-70.
    341. A weight-adjusted Peto's test when cause of death is not assigned. Environmental and Ecological Statistics. 12:95-113.
    342. Model diagnostic tests for selecting informative correlation structure in correlated data. Biometrika. 95:891-905.
    343. Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer. Breast Cancer Research and Treatment. 158:67-77.
    344. TP53 alterations correlate with response to VEGF/VEGFR inhibitors. Molecular Cancer Therapeutics. 15:2475-2485.
    345. Calibrating the prior distribution for a normal model with conjugate prior. Journal of Statistical Computation and Simulation. 85:3108-3128.
    346. Erlotinib and the risk of oral cancer the erlotinib Prevention of Oral Cancer (EPOC) randomized clinical trial. JAMA oncology. 2:209-216.
    347. Phase II trial design with Bayesian adaptive randomization and predictive probability. Journal of the Royal Statistical Society. Series C: Applied Statistics. 61:219-235.
    348. Rebuttal to the response of Chou. Cancer Research. 71:2798-2800.
    349. Improvement of clinical response and biomarkers by Camellia sinensis (green tea) extract in patients with high-risk oral premalignant lesions. Focus on Alternative and Complementary Therapies. 15:122-123.
    350. The BATTLE-2 study. Journal of Clinical Oncology. 34:3638-3647.
    351. Concordance of oral HPV prevalence between patients with oropharyngeal cancer and their partners. Infectious Agents and Cancer. 11.
    352. Genomic heterogeneity of multiple synchronous lung cancer. Nature Communications. 7.
    353. A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer. Oncotarget. 6:14139-14152.
    354. Long-term results of a randomized phase III trial of TPF induction chemotherapy followed by surgery and radiation in locally advanced oral squamous cell carcinoma. Oncotarget. 6:18707-18714.
    355. Bayesian Two-Stage Biomarker-Based Adaptive Design for Targeted Therapy Development. Statistics in Biosciences.
    356. Image analysis-based assessment of PD-L1 and tumor-associated immune cells density supports distinct intratumoral microenvironment groups in non-small cell lung carcinoma patients. Clinical Cancer Research. 22:6278-6289.
    357. A web-based simulator for sample size and power estimation in animal carcinogenicity studies. Journal of Statistical Software. 7:1-36.
    358. Erratum. Cancer. 118:6301.
    359. Testing hypotheses about medical test accuracy. Journal of Applied Statistics. 42:1106-1119.
    360. Cancer therapy directed by comprehensive genomic profiling. Cancer Research. 76:3690-3701.
    361. Interleukin-11 Receptor Is a Candidate Target for Ligand-Directed Therapy in Lung Cancer. American Journal of Pathology. 186:2162-2170.
    362. Phase II study of gefitinib in patients with advanced salivary gland cancers. Head and Neck. 37:644-649.
    363. p53 expression and tumor proliferative activity in testicular germ-cell tumors. International Journal of Oncology. 9:787-793.
    364. The effective use of a local area network for the data management of clinical and nutritional data from a multicenter clinical trial. Controlled Clinical Trials. 7:234.
    365. Modulation of EZH2 expression by MEK-ERK or PI3K-AKT signaling in lung cancer is dictated by different KRAS oncogene mutations. Cancer Research. 76:675-685.
    366. Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer. EBioMedicine.
    367. β-carotene may not prevent second head and neck cancer. Evidence-based Oncology. 2:200-201.
    368. A better confidence interval for kappa («) on measuring agreement between two raters with binary outcomes. Journal of Computational and Graphical Statistics. 3:301-321.
    369. A Versatile One-Dimensional Distribution Plot. American Statistician. 51:353-358.
    370. Intensity modulated proton therapy versus intensity modulated photon radiation therapy for oropharyngeal cancer. International Journal of Radiation Oncology Biology Physics. 95:1107-1114.
    371. Adaptive Clinical Trials. Therapeutic Innovation and Regulatory Science. 48:20-30.
    372. Protective effects of in vivo 13-cis-retinoic acid treatment against mutagen-induced genetic damage. Cancer Research Therapy and Control. 4:81-85.
    373. Erratum. Journal of the National Cancer Institute. 103:613.
    374. Activation of insulin-like growth factor 1 receptor in patients with non-small cell lung cancer. Oncotarget. 6:16746-16756.
    375. Outcome-adaptive randomization for a delayed outcome with a short-term predictor. Statistics in Medicine. 33:4029-4042.
    376. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy. The Lancet Oncology. 17:1672-1682.
    377. Adaptive clinical trial designs in oncology. Chinese Clinical Oncology. 3.
    378. Cancer Chemoprevention. 711-720.
    LEE's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (841)
    Co-Authors (176)
    Similar People (60)
    Same Department Expand Description